KR102609952B1 - Ample type cosmetic composition improving skin elasticity, Manufacturing method of the same and Ample type comsmetics improving skin elasticity - Google Patents
Ample type cosmetic composition improving skin elasticity, Manufacturing method of the same and Ample type comsmetics improving skin elasticity Download PDFInfo
- Publication number
- KR102609952B1 KR102609952B1 KR1020210183402A KR20210183402A KR102609952B1 KR 102609952 B1 KR102609952 B1 KR 102609952B1 KR 1020210183402 A KR1020210183402 A KR 1020210183402A KR 20210183402 A KR20210183402 A KR 20210183402A KR 102609952 B1 KR102609952 B1 KR 102609952B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- liquid
- parts
- skin elasticity
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 65
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims description 37
- 230000037394 skin elasticity Effects 0.000 title claims description 37
- 239000000284 extract Substances 0.000 claims abstract description 152
- 244000060701 Kaempferia pandurata Species 0.000 claims abstract description 80
- 235000016390 Uvaria chamae Nutrition 0.000 claims abstract description 78
- 230000006872 improvement Effects 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 116
- 238000003756 stirring Methods 0.000 claims description 48
- 239000000469 ethanolic extract Substances 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 35
- 108010035532 Collagen Proteins 0.000 claims description 32
- 102000008186 Collagen Human genes 0.000 claims description 32
- 229920001436 collagen Polymers 0.000 claims description 32
- 241000196324 Embryophyta Species 0.000 claims description 28
- 239000012223 aqueous fraction Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 18
- 239000004615 ingredient Substances 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
- 239000003995 emulsifying agent Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 14
- 230000003750 conditioning effect Effects 0.000 claims description 13
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003708 ampul Substances 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 239000003205 fragrance Substances 0.000 claims description 10
- 239000003906 humectant Substances 0.000 claims description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 9
- 241000186660 Lactobacillus Species 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 229960005305 adenosine Drugs 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 239000006166 lysate Substances 0.000 claims description 9
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 8
- 229940059958 centella asiatica extract Drugs 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 7
- 235000017945 Matricaria Nutrition 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 7
- 229960000458 allantoin Drugs 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 235000020688 green tea extract Nutrition 0.000 claims description 7
- 229940094952 green tea extract Drugs 0.000 claims description 7
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- 229940092258 rosemary extract Drugs 0.000 claims description 7
- 235000020748 rosemary extract Nutrition 0.000 claims description 7
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 6
- 240000000171 Crataegus monogyna Species 0.000 claims description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 6
- 235000005206 Hibiscus Nutrition 0.000 claims description 6
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 6
- 240000000249 Morus alba Species 0.000 claims description 6
- 235000008708 Morus alba Nutrition 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 230000003020 moisturizing effect Effects 0.000 claims description 6
- 235000020737 peppermint extract Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 5
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 5
- -1 glycerol-26 Chemical compound 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229940031722 methyl gluceth-20 Drugs 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- 244000192528 Chrysanthemum parthenium Species 0.000 claims 3
- 240000000785 Tagetes erecta Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 41
- 230000037303 wrinkles Effects 0.000 abstract description 23
- 230000002087 whitening effect Effects 0.000 abstract description 8
- 239000000419 plant extract Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 210000003491 skin Anatomy 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- LYDZCXVWCFJAKQ-ZFGGDYGUSA-N Panduratin A Chemical compound OC1=CC(OC)=CC(O)=C1C(=O)[C@H]1[C@H](C=2C=CC=CC=2)CC=C(C)[C@H]1CC=C(C)C LYDZCXVWCFJAKQ-ZFGGDYGUSA-N 0.000 description 23
- LYDZCXVWCFJAKQ-UHFFFAOYSA-N nicolaioidesin A Natural products OC1=CC(OC)=CC(O)=C1C(=O)C1C(C=2C=CC=CC=2)CC=C(C)C1CC=C(C)C LYDZCXVWCFJAKQ-UHFFFAOYSA-N 0.000 description 23
- 238000005259 measurement Methods 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 13
- 239000011049 pearl Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 10
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 8
- 101710108790 Stromelysin-1 Proteins 0.000 description 8
- 102100030416 Stromelysin-1 Human genes 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000012086 standard solution Substances 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 7
- 108060008724 Tyrosinase Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 244000042664 Matricaria chamomilla Species 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000001120 cytoprotective effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008406 cosmetic ingredient Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229930193739 panduratin Natural products 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ORJDDOBAOGKRJV-CQSZACIVSA-N (2S)-Pinocembrin Natural products C1([C@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-CQSZACIVSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000001432 Calendula officinalis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ORJDDOBAOGKRJV-UHFFFAOYSA-N Dihydrotectochrysin Natural products O1C2=CC(OC)=CC(O)=C2C(=O)CC1C1=CC=CC=C1 ORJDDOBAOGKRJV-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000013412 Kaempferia pandurata Nutrition 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- ORJDDOBAOGKRJV-AWEZNQCLSA-N pinostrobin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-AWEZNQCLSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- XWZAWHJNTHSHGD-SIDOVBMKSA-N (2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanamide Polymers CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccccc1)C(N)=O XWZAWHJNTHSHGD-SIDOVBMKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- DJXNLVJQMJNEMN-UHFFFAOYSA-N 2-[difluoro(methoxy)methyl]-1,1,1,2,3,3,3-heptafluoropropane Chemical compound COC(F)(F)C(F)(C(F)(F)F)C(F)(F)F DJXNLVJQMJNEMN-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 description 1
- 244000271437 Bambusa arundinacea Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- RTIXKCRFFJGDFG-UHFFFAOYSA-N Chrysin Natural products C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 241001123633 Galactomyces Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000218033 Hibiscus Species 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940002386 calendula officinalis extract Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- QMIFIFIYYPUVNU-ACMTZBLWSA-L copper (2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-imidazol-1-id-4-ylpropanoyl]amino]hexanoate Chemical compound [Cu+2].NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=C[N-]C=N1 QMIFIFIYYPUVNU-ACMTZBLWSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 229940119204 hibiscus sabdariffa flower extract Drugs 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229940104872 methyl perfluoroisobutyl ether Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229940116733 morus alba leaf extract Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000037333 procollagen synthesis Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 천연소재 유래 추출물을 이용한 화장료에 관한 것으로서, 좀 더 구체적으로 설명하면, 핑거루트뿌리줄기 추출물 등 천연식물 추출물을 이용한 화장료로서, 피부 미백 및 피부 주름 개선 효과가 우수한 화장료, 이를 제조하는 방법 및 이를 이용한 화장품에 관한 것이다.The present invention relates to a cosmetic using extracts derived from natural materials. More specifically, it relates to a cosmetic using natural plant extracts such as finger root rhizome extract, which has excellent skin whitening and skin wrinkle improvement effects, and a method for manufacturing the same. and cosmetics using the same.
Description
본 발명은 핑거루트뿌리줄기 추출물과 다양한 천연식물 유래추출물을 이용한 피부 미백 및 피부 주름 개선 효과가 우수한 앰플 재형의 피부탄력 화장료, 이를 제조하는 방법 및 이를 이용한 앰플 제형 화장품에 관한 것이다.The present invention relates to an ampoule-type skin elasticity cosmetic with excellent skin whitening and skin wrinkle improvement effects using finger root rhizome extract and various natural plant-derived extracts, a method for manufacturing the same, and an ampoule-type cosmetic using the same.
최근, 피부과학을 통한 생리적 메커니즘에 대한 연구 및 효능이 한 계 높은 새로운 소재로서 천연물로부터 유효성분을 추출 정제하는 연구로부터, 단순히 피부보호 차원에서 머물던 화장품이 그 효능에 있어서 피부개선의 범주까지 확대된 기능성 화장품에 대한 수요가 급증하고 있다.Recently, as a result of research on physiological mechanisms through dermatology and research on extracting and refining active ingredients from natural products as a new material with high efficacy, cosmetics that were simply used to protect the skin have expanded their efficacy to the scope of skin improvement. Demand for functional cosmetics is rapidly increasing.
특히, 기능성 화장품 중에서 한 제품에 두 가지 이상의 기능성을 갖는 복합기능성 화장품(예로서, 주름개선기능과 미백기능을 동시에 포함)에 대한 생산액 및 시장 성장률이 단일기능성 화장품에 비해 월등히 높게 나타나고 있다. 그러나 이러한 요구를 현재 시판되고 있는 대부분의 화장품들이 충분히 만족시키지 못하고 있는 실정이다.In particular, among functional cosmetics, the production amount and market growth rate for multi-functional cosmetics that have two or more functions in one product (for example, including both wrinkle-improving and whitening functions) are significantly higher than those of single-functional cosmetics. However, most cosmetics currently on the market do not fully satisfy these requirements.
핑거루트(fingerroot, 학명: Boesenbergia pandurata)는 동남아시아에서 자생하는 생강과의 식물로 피클, 카레, 음료 등 아시아 전통요리뿐만 아니라, 출산을 위한 강장제, 위통, 설사, 헛배부름, 소화불량, 궤양치료제, 백혈구예방제, 비용보조제 등 다양한 용도로 사용되어 왔다.Fingerroot (Scientific name: Boesenbergia pandurata) is a plant in the ginger family that grows in Southeast Asia and is used not only in traditional Asian dishes such as pickles, curries, and drinks, but also as a tonic for childbirth, stomach pain, diarrhea, flatulence, indigestion, and ulcer treatment. It has been used for various purposes, including as a leukocyte preventive agent and as a cost supplement.
핑거루트는 소화불량, 위염을 비롯한 헬리코박터 파일로리 박테리아의 감염을 억제하는 플로보노이드 성분을 함유하고 있으며, 세포보호효과가 있는 피노스트로빈 성분이 함유되어 있어 위 점액을 증가시켜 위궤양 형성면적을 감소시킴으로써 소화성궤양 치료에도 효과적이다. 그 외에도 암세포의 성장을 억제할 수 있는 플라보노이드 유도체, 피노셈브린, 피노스트로빈, 일피네틴, 타다모닌, 판두라타, 판두라틴A 등의 성분이 함유되어 있으며, 특히 판두라타(pandurata) 성분은 암세포 성장을 억제하고, 판두라틴A(panduratin A) 성분은 전립선암 및 대장암에 대한 예방효과가 있는 것으로 알려져 있다.Finger root contains flavonoids that inhibit Helicobacter pylori bacteria infection, including indigestion and gastritis, and pinostrobin, which has a cell-protective effect, increases gastric mucus and reduces the area of gastric ulcer formation. It is also effective in treating peptic ulcers. In addition, it contains ingredients such as flavonoid derivatives, pinocembrin, pinostrobin, ilpinetin, tadamonin, pandurata, and panduratin A, which can inhibit the growth of cancer cells, especially pandurata. The ingredient inhibits the growth of cancer cells, and panduratin A is known to have a preventive effect on prostate cancer and colon cancer.
최근 문헌에 의하면, 생강과 식물, 특히 핑거루트의 뿌리에서 추출한 기능성 원료인 판두라틴(Panduratin)은 핑거루트의 뿌리에서 추출한 밝은 황갈색의 분말로서, 식품의약품안전처에서 2013년 건강기능식품의 기능성 원료로 인정되었으며 생리활성기능 2등급을 받은 바 있다.According to recent literature, Panduratin, a functional ingredient extracted from the roots of ginger plants, especially finger roots, is a light yellow-brown powder extracted from the roots of finger roots, and was designated as a functional ingredient for health functional foods by the Ministry of Food and Drug Safety in 2013. It has been recognized as having a physiological activity level of 2.
판두라틴은 핑거루트라는 식물의 뿌리에서 추출한 밝은 황갈색의 분말로서, 식품의약품안전처에서 2013년 건강기능식품의 기능성 원료로 인정(생리활성기능 2등급)되었으며, 자외선에 의한 피부 손상으로부터 피부 건강을 유지하고 체내 에너지 항상성 유지를 위한 센서 단백질인 ‘AMPK(AMP-activated protein kinase)’를 활성화시켜 체지방을 감소하는데 기여하는 것으로 알려져 있다.Panduratin is a light yellow-brown powder extracted from the roots of a plant called fingerroot. It was recognized by the Ministry of Food and Drug Safety as a functional ingredient for health functional foods in 2013 (
그러나 핑거루트뿌리 추출물 성분 중 하나인 판두라틴은 강한 독성이 있어 사용에 주의를 요하며, 이를 이용한 기능성 화장료로 적용하는데 한계가 있는 실정이다.However, panduratin, one of the components of finger root extract, is highly toxic, so caution is required when using it, and there are limitations in applying it as a functional cosmetic.
본 발명자들은 천연재료를 이용한 복합기능성 화장품에 대한 시장의 요구가 높아짐에 따라, 약간의 독성이 있는 단점이 있지만 피부 항상성 유지에 효과가 있는 핑거루트 추출물인 판두라틴의 독성을 제거하는 방법을 개발하였고, 이와 같이 독성이 제거된 핑거루트뿌리줄기 추출물을 이용하여 핑거루트뿌리줄기 추출물의 유익 성분을 화장료로 적용하면서 이 외 다른 천연 식물 유래 추출물과의 혼합 적용함으로써, 피부 미백, 주름, 보습 등의 우수한 효과에 의해 피부 항성성, 피부 상태를 개선할 수 있는 고기능성 화장료, 이의 제조방법 및 이를 이용한 화장품을 제공하고자 한다.As the market demand for multi-functional cosmetics using natural ingredients increases, the present inventors developed a method to remove the toxicity of panduratin, a finger root extract that has the disadvantage of being slightly toxic but is effective in maintaining skin homeostasis. , By using the finger root rhizome extract from which toxicity has been removed, the beneficial ingredients of the finger root rhizome extract are applied as cosmetics and mixed with other natural plant-derived extracts to provide excellent skin whitening, anti-wrinkle, and moisturizing properties. The aim is to provide highly functional cosmetics that can improve skin elasticity and skin condition, a manufacturing method thereof, and cosmetics using the same.
상술한 과제를 해결하기 위한, 본 발명의 앰플 타입의 피부탄력 개선 화장료는 제1액, 제2액, 제3액, 제4액 및 제5액을 포함하며, 상기 제1액은 점도조절제 및 정제수를 포함하고, 상기 제2액은 잔탄검; 및 글리세린 및 부틸렌글라이콜을 포함하는 보습제;를 포함하며, 상기 제3액은 메틸글루세스-20, 나이아신아마이드, 글리세레스-26, 소듐하이알루로네이트, 알란토인, 하이드롤라이즈드 콜라겐(Hydrolyzed Collagen) 및 아데노신 중에서 선택된 1종 이상을 포함하는 피부컨디셔닝제; 습윤제; 및 용매;를 포함하고, 상기 제4액은 유화제, 향료 및 용매를 포함하며, 상기 제5액은 진주 추출물 및 천연식물 복합 추출물을 포함하는 기능성 추출물; 락토바실러스발효 용해물; 및 콜라겐 합성 촉진제;를 포함한다.In order to solve the above-described problem, the ampoule type cosmetic for improving skin elasticity of the present invention includes a first liquid, a second liquid, a third liquid, a fourth liquid, and a fifth liquid, and the first liquid contains a viscosity modifier and It contains purified water, and the second liquid includes xanthan gum; and a moisturizing agent containing glycerin and butylene glycol, wherein the third liquid contains methylglucet-20, niacinamide, glycereth-26, sodium hyaluronate, allantoin, and hydrolyzed collagen (Hydrolyzed Collagen) and adenosine; a skin conditioning agent containing one or more selected from among; humectant; and a solvent; wherein the fourth liquid contains an emulsifier, fragrance and solvent, and the fifth liquid includes a functional extract including a pearl extract and a natural plant complex extract; Lactobacillus fermentation lysate; and collagen synthesis promoters.
또한, 본 발명은 상기 앰플 타입의 피부탄력 개선 화장료를 제조하는 방법에 관한 것으로서, 반응기에 정제수 및 점도조절제를 투입한 후, 3000 ~ 4000rpm 하에서 30 ~ 50분 동안 교반을 수행하여 제1액을 제조하는 1단계; 제1액이 제조된 반응기에 제2액을 투입한 후, 2000 ~ 3000rpm 하에서 20 ~ 40분 동안 교반을 수행하는 2단계; 2단계를 수행한 반응기에 제3액을 투입한 후, 1500 ~ 2500rpm 하에서 20 ~ 40분 동안 교반을 수행하는 3단계; 3단계를 수행한 반응기에 제4액을 투입한 후, 1500 ~ 2500rpm 하에서 20 ~ 40분 동안 교반을 수행하는 4단계; 4단계를 수행한 반응기에 pH 조절제를 투입한 후, 2000 ~ 3000rpm 하에서 20 ~ 40분 동안 교반을 수행하는 5단계; 및 5단계를 수행한 반응기에 제5액을 투입한 후, 1500 ~ 2500rpm 하에서 20 ~ 40분 동안 교반을 수행하는 6단계;를 포함하는 공정을 수행하여 제조할 수 있다.In addition, the present invention relates to a method of producing the ampoule type cosmetic for improving skin elasticity, wherein purified water and a viscosity modifier are added to the reactor, and then stirred for 30 to 50 minutes at 3000 to 4000 rpm to prepare the first liquid.
또한, 6단계를 수행한 혼합액을 여과 및 탈포하는 7단계; 및 7단계를 수행한 혼합액을 숙성시키는 8단계;를 더 수행하여 제조할 수 있다.In addition, step 7 of filtering and defoaming the mixed solution obtained from step 6; And it can be manufactured by further performing
또한, 본 발명은 앞서 설명한 방법으로 제조한 화장료를 이용한 피부탄력 개선 화장품에 관한 것으로서, 앰플 제형의 화장품을 제공할 수 있다.In addition, the present invention relates to cosmetics for improving skin elasticity using cosmetics prepared by the method described above, and can provide cosmetics in an ampoule formulation.
본 발명의 화장료는 피부 트러블이 없으면서 보습성이 우수하면서 피부 미백 개선, 피부 주름 개선 효과가 우수한 바, 이를 이용하여 고기능성 천연소재 유래의 화장품을 제공할 수 있다.The cosmetic of the present invention does not cause skin trouble, has excellent moisturizing properties, has excellent skin whitening and skin wrinkle improvement effects, and can be used to provide highly functional cosmetics derived from natural materials.
도 1은 실험예 1에서 실시한 용매별 핑거루트뿌리줄기 추출물의 세포 독성 측정결과이다.
도 2는 실험예 2에서 실시한 용매별 핑거루트뿌리줄기 추출물의 세포 보호 측정 결과이다.
도 3은 실험예 2에서 실시한 용매별 핑거루트뿌리줄기 추출물의 세포 보호 효과 측정 결과이다.
도 4는 실험예 3에서 실시한 핑거루트뿌리줄기 에탄올 추출물의 각 분획물에 대한 세포독성 측정 결과이다.
도 5는 실험예 4에서 실시한 핑거루트뿌리줄기 에탄올 추출물의 각 분획물에 대한 세포 보호 효과 측정 결과이다.
도 6 및 도 7은 실험예 4에서 실시한 핑거루트뿌리줄기 에탄올 추출물의 물 분획물의 세포독성 및 세포 보호 효과 측정 결과이다.
도 8은 실험예 5에서 실시한 핑거루트뿌리줄기 에탄올 추출물의 물 분획물에 대한 세포 내 콜라겐 영향 평가 결과이다.
도 9는 실험예 6에서 실시한 핑거루트뿌리줄기 에탄올 추출물의 물 분획물에 대한 세포 내 항산화 영향 평가 결과이다.Figure 1 shows the cytotoxicity measurement results of the finger root rhizome extract for each solvent conducted in Experimental Example 1.
Figure 2 shows the cell protection measurement results of finger root rhizome extract for each solvent conducted in Experimental Example 2.
Figure 3 shows the results of measuring the cell protection effect of finger root rhizome extract for each solvent conducted in Experimental Example 2.
Figure 4 shows the cytotoxicity measurement results for each fraction of the ethanol extract of finger root rhizome performed in Experimental Example 3.
Figure 5 shows the results of measuring the cell protection effect for each fraction of the ethanol extract of finger root rhizome performed in Experimental Example 4.
Figures 6 and 7 show the results of measuring the cytotoxicity and cytoprotective effects of the water fraction of the ethanol extract of finger root rhizomes conducted in Experimental Example 4.
Figure 8 shows the results of evaluating the effect of intracellular collagen on the water fraction of the ethanol extract of finger root rhizome performed in Experimental Example 5.
Figure 9 shows the results of evaluating the intracellular antioxidant effect of the water fraction of the ethanol extract of finger root rhizomes conducted in Experimental Example 6.
본 발명의 상세한 설명에서 사용되는 "피부 개선"이란 피부의 손상, 질환 증세를 억제 또는 지연시키거나, 질환증세를 호전시키거나, 피부의 건강 상태를 향상시키는 모든 행위 또는 효과를 의미한다.“Skin improvement” as used in the detailed description of the present invention means any action or effect that suppresses or delays skin damage or disease symptoms, improves disease symptoms, or improves the health status of the skin.
본 발명의 상세한 설명에서 사용되는 "추출물(extract)"이란 천연물로부터 분리된 활성성분 즉, 목적하는 활성을 보이는 물질을 의미한다. 상기추출물은 물, 유기용매 또는 이들의 혼합용매를 이용하는 추출 과정으로 획득할 수 있으며, 추출물 이의 건조분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다. 또한, 상기 추출물에는 상기 추출 과정을 거친 추출물을 분획한 것도 포함된다.“Extract” used in the detailed description of the present invention refers to an active ingredient isolated from a natural product, that is, a substance showing the desired activity. The extract can be obtained through an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes the extract's dry powder or any form formulated using it. In addition, the extract includes fractions of the extract that have undergone the extraction process.
본 발명의 상세한 설명에서 다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가진 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless otherwise defined in the detailed description of the present invention, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the technical field to which the present invention pertains. there is. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and should not be interpreted in an ideal or excessively formal sense unless explicitly defined in the present application. No.
이하에서 본 발명의 앰플 타입의 피부탄력 개선 화장료 및 이를 제조하는 방법을 통해서 본 발명을 더욱 자세하게 설명한다.Hereinafter, the present invention will be described in more detail through the ampoule type skin elasticity improvement cosmetic of the present invention and the method of manufacturing the same.
본 발명의 화장료는 제1액 100 중량부에 대하여, 제2액 7 ~ 12 중량부, 제3액 12 ~ 16 중량부, 제4액 0.2 ~ 1.0 중량부 및 제5액 13 ~ 16 중량부를 포함하며, 바람직하게는 제1액 100 중량부에 대하여, 제2액 7 ~ 11 중량부, 제3액 13 ~ 15.5 중량부, 제4액 0.25 ~ 0.8 중량부 및 제5액 13.5 ~ 15.5 중량부를 포함하고, 더욱 바람직하게는 바람직하게는 제1액 100 중량부에 대하여, 제2액 7.5 ~ 10.0 중량부, 제3액 13.2 ~ 15.0 중량부, 제4액 0.25 ~ 0.50 중량부 및 제5액 14.0 ~ 15.2 중량부를 포함할 수 있다.The cosmetic of the present invention includes 7 to 12 parts by weight of the second liquid, 12 to 16 parts by weight of the third liquid, 0.2 to 1.0 parts by weight of the fourth liquid, and 13 to 16 parts by weight of the fifth liquid, based on 100 parts by weight of the first liquid. and preferably, based on 100 parts by weight of the first liquid, 7 to 11 parts by weight of the second liquid, 13 to 15.5 parts by weight of the third liquid, 0.25 to 0.8 parts by weight of the fourth liquid, and 13.5 to 15.5 parts by weight of the fifth liquid. And, more preferably, based on 100 parts by weight of the first liquid, 7.5 to 10.0 parts by weight of the second liquid, 13.2 to 15.0 parts by weight of the third liquid, 0.25 to 0.50 parts by weight of the fourth liquid, and 14.0 to 14.0 parts by weight of the fifth liquid. It may contain 15.2 parts by weight.
상기 제1액은 화장료의 용매 역할을 하는 것으로서, 점도조절제 0.10 ~ 0.25 중량% 및 잔량의 정제수를 포함하고, 바람직하게는 점도조절제 0.10 ~ 0.18 중량% 및 잔량의 정제수를 포함할 수 있다. 이때, 점도조절제 함량이 0.25 중량%를 초과하면 초기 점도가 너무 높아져서 제2액 내지 제4액 성분이 제1액에 적절하게 용해되지 않고, 조성물의 혼화성이 떨어질 수 있다. 그리고 상기 점도조절제로는 화장품 업계에서 사용하는 일반적인 점도조절제를 사용할 수 있으며, 바람직한 일례로는 아크릴레이트/(C10~30알킬)아크릴레이트 크로스 폴리머(acrylate/(/(C10~30 alklyl)acrylate cross polymer)를 사용할 수 있다.The first liquid serves as a solvent for cosmetics and contains 0.10 to 0.25% by weight of a viscosity modifier and the remaining amount of purified water, and preferably may contain 0.10 to 0.18% by weight of the viscosity modifier and the remaining amount of purified water. At this time, if the viscosity modifier content exceeds 0.25% by weight, the initial viscosity may become too high, so the components of the second to fourth liquids may not be properly dissolved in the first liquid, and the miscibility of the composition may be reduced. And, as the viscosity modifier, a general viscosity modifier used in the cosmetics industry can be used. A preferred example is acrylate/(C 10-30 alkyl)acrylate cross polymer (acrylate/(/(C 10-30 alklyl)acrylate). cross polymer) can be used.
다음으로, 화장료 성분 중 상기 제2액은 잔탄검 0.5 ~ 1.5 중량% 및 제2액 전체 중량 중 나머지 잔량의 보습제를 포함할 수 있고, 바람직하게는 잔탄검 0.6 ~ 1.0 중량% 및 제2액 전체 중량 중 나머지 잔량의 보습제를 포함할 수있다. 그리고, 상기 보습제는 글리세린 및 부틸렌글라이콜 중에서 선택된 1종 이상을 포함할 수 있고, 바람직하게는 글리세린 및 부틸렌글라이콜을 1 : 0.5 ~ 1.5 중량비로 포함할 수 있다.Next, among the cosmetic ingredients, the second liquid may include 0.5 to 1.5% by weight of xanthan gum and the remaining amount of a moisturizer based on the total weight of the second liquid, preferably 0.6 to 1.0% by weight of xanthan gum and the entire second liquid. The remainder of the weight may include moisturizer. In addition, the moisturizing agent may include one or more selected from glycerin and butylene glycol, and preferably may include glycerin and butylene glycol in a weight ratio of 1:0.5 to 1.5.
다음으로, 화장료 성분 중 상기 제3액은 피부컨디셔닝제 77 ~ 85 중량%, 습윤제 1.0 ~ 3.0 중량% 및 제3액 전체 중량 중 나머지 잔량의 용매를 포함할 수 있고, 바람직하게는 피부컨디셔닝제 77.5 ~ 83.0 중량%, 습윤제 1.2 ~ 2.5 중량% 및 나머지 잔량의 용매를 포함할 수 있으며, 더욱 바람직하게는 피부컨디셔닝제 78.2 ~ 81.0 중량%, 습윤제 1.3 ~ 2.2 중량% 및 나머지 잔량의 용매를 포함할 수 있다.Next, among the cosmetic ingredients, the third liquid may include 77 to 85% by weight of a skin conditioning agent, 1.0 to 3.0% by weight of a humectant, and the remaining amount of solvent based on the total weight of the third liquid, preferably 77.5% by weight of the skin conditioning agent. It may contain ~ 83.0% by weight, 1.2 ~ 2.5% by weight of humectant, and the remaining amount of solvent, and more preferably may contain 78.2 ~ 81.0% by weight of skin conditioning agent, 1.3 ~ 2.2% by weight of humectant, and the remaining amount of solvent. there is.
제3액 성분 중 상기 피부컨디셔닝제는 메틸글루세스-20(Methyl Gluceth-20), 나이아신아마이드, 글리세레스-26(Glycereth-26), 소듐하이알루로네이트(Sodium hyaluronate), 알란토인(Allantoin), 하이드롤라이즈드 콜라겐(Hydrolyzed Collagen) 및 아데노신(Adenosine) 중에서 선택된 1종 이상을 포함할 수 있으며, 바람직하게는 메틸글루세스-20 100 중량부에 대하여, 나이아신아마이드 50 ~ 80 중량부, 글리세레스-26 30 ~ 60 중량부, 소듐하이알루로네이트 20 ~ 40 중량부, 알란토인 5 ~ 20 중량부, 하이드롤라이즈드 콜라겐 10 ~ 30 중량부 및 아데노신 1 ~ 5 중량부를 포함할 수 있으며, 더욱 바람직하게는 메틸글루세스-20 100 중량부에 대하여, 나이아신아마이드 60 ~ 72 중량부, 글리세레스-26 40 ~ 55 중량부, 소듐하이알루로네이트 30 ~ 40 중량부, 알란토인 6 ~ 15 중량부, 하이드롤라이즈드 콜라겐 12 ~ 25 중량부 및 아데노신 1 ~ 3 중량부를 포함할 수 있다.Among the third liquid ingredients, the skin conditioning agents include Methyl Gluceth-20, Niacinamide, Glycereth-26, Sodium hyaluronate, Allantoin, It may contain one or more types selected from Hydrolyzed Collagen and Adenosine, preferably 50 to 80 parts by weight of niacinamide, and glycerol-20, based on 100 parts by weight of methylglucet-20. 26 30 to 60 parts by weight, 20 to 40 parts by weight of sodium hyaluronate, 5 to 20 parts by weight of allantoin, 10 to 30 parts by weight of hydrolyzed collagen, and 1 to 5 parts by weight of adenosine, more preferably. Based on 100 parts by weight of methylglucet-20, 60 to 72 parts by weight of niacinamide, 40 to 55 parts by weight of glycerol-26, 30 to 40 parts by weight of sodium hyaluronate, 6 to 15 parts by weight of allantoin, hydrol. It may contain 12 to 25 parts by weight of risen collagen and 1 to 3 parts by weight of adenosine.
제3액 성분 중 상기 습윤제는 트레할로오스를 포함할 수 있으며, 상기 용매는 1,2-헥산 다이올(1,2-hexane diol)을 포함할 수 있다.Among the third liquid components, the wetting agent may include trehalose, and the solvent may include 1,2-hexane diol.
다음으로, 화장료 성분 중 상기 제4액은 유화제 20 ~ 28 중량%, 향료 5 ~ 20 중량% 및 나머지 잔량의 용매를 포함할 수 있고, 바람직하게는 유화제 22 ~ 26 중량%, 향료 5 ~ 15 중량% 및 나머지 잔량의 용매를 포함할 수 있으며, 더욱 바람직하게는 바람직하게는 유화제 22.5 ~ 25.5 중량%, 향료 5 ~ 12 중량% 및 나머지 잔량의 용매를 포함할 수 있다.Next, the fourth liquid among the cosmetic ingredients may include 20 to 28% by weight of emulsifier, 5 to 20% by weight of fragrance, and the remaining amount of solvent, preferably 22 to 26% by weight of emulsifier and 5 to 15% by weight of fragrance. % and the remaining amount of solvent, and more preferably, 22.5 to 25.5% by weight of emulsifier, 5 to 12% by weight of fragrance, and the remaining amount of solvent.
제4액 성분 중 상기 유화제는 화장료 조성 간 혼화성 및 조성의 유화성 증대 역할을 하는 것으로서, 피이지-60하이드로제네이티드캐스터오일, 폴리솔베이트 60(polysorbate 60), 스테아릭애씨드(stearic acid) 및 솔비탄세스퀴올리에이트(Sorbitan sesquioleate) 중에서 선택된 1종 이상을 포함할 수 있고, 바람직하게는 피이지-60하이드로제네이티드캐스터오일을 포함할 수 있다.Among the fourth liquid components, the emulsifier serves to increase the miscibility and emulsibility of the cosmetic composition, and includes PEG-60 hydrogenated castor oil,
제4액 성분 중 상기 용매는 에탄올 수용액을 사용하는 것이 좋으며, 상기 향료의 종류는 피부 트러블을 유발하거나, 본 발명 화장료의 기능을 저해하지 않는다면 당업계에서 사용하는 일반적인 향료를 사용할 수 있다.Among the fourth liquid components, it is recommended to use an ethanol aqueous solution as the solvent, and the type of fragrance may be any general fragrance used in the art as long as it does not cause skin trouble or impede the function of the cosmetic of the present invention.
다음으로, 화장료 성분 중 상기 제5액은 락토바실러스발효 용해물 3.5 ~ 8.0 중량%, 콜라겐 합성 촉진제 1.0 ~ 2.5 중량%, 및 제5액 전체 중량 중 나머지 잔량의 기능성 추출물을 포함할 수 있고, 바람직하게는 락토바실러스발효 용해물 3.8 ~ 6.5 중량%, 콜라겐 합성 촉진제 1.1 ~ 2.0 중량% 및 제5액 전체 중량 중 나머지 잔량의 기능성 추출물을 포함할 수 있다. 이때, 제5액 성분 중 락토바실러스발효 용해물은 기능성 추출물이 숙성을 증진시키는 역할을 하는 것으로서 함량이 3.5 중량% 미만이면 기능성 추출물 숙성이 잘 되지 않아서 피부 트러블을 유발시킬 수 있으며, 8.0 중량%를 초과하여 사용하는 것은 비경제적이다.Next, among the cosmetic ingredients, the fifth liquid may include 3.5 to 8.0% by weight of Lactobacillus fermentation lysate, 1.0 to 2.5% by weight of collagen synthesis accelerator, and the remaining amount of functional extract based on the total weight of the fifth liquid, preferably. It may include 3.8 to 6.5% by weight of Lactobacillus fermentation lysate, 1.1 to 2.0% by weight of collagen synthesis promoter, and the remaining amount of functional extract based on the total weight of the fifth liquid. At this time, among the fifth liquid components, the Lactobacillus fermentation lysate plays a role in promoting the ripening of the functional extract. If the content is less than 3.5% by weight, the functional extract does not ripen well and may cause skin problems. 8.0% by weight Excessive use is uneconomical.
그리고, 콜라겐 합성 촉진제는 피부에 흡수되어 피부의 콜라겐 합성을 촉진하는 역할을 하는 것으로서, 알에이치-올리고펩타이드-1를 사용할 수 있다. 그리고, 콜라겐 합성 촉진제 함량이 1.0 중량% 미만이면 그 사용량이 너무 적어서 피부의 콜라겐 합성 촉진 효과가 미비하여 피부 주름 개선 증대 효과가 미비할 수 있고, 2.5 중량%를 초과하여 사용하면 다른 조성들의 혼화성을 방해할 수 있으므로 상기 범위 내로 사용하는 것이 좋다.In addition, the collagen synthesis promoter is absorbed into the skin and plays a role in promoting collagen synthesis in the skin, and RH-oligopeptide-1 can be used. In addition, if the collagen synthesis promoter content is less than 1.0% by weight, the amount used is too small, so the effect of promoting collagen synthesis in the skin is minimal, and the effect of improving skin wrinkles may be minimal, and if used in excess of 2.5% by weight, the miscibility of other compositions may be reduced. It is recommended to use it within the above range as it may interfere with it.
또한, 상기 기능성 추출물은 진주 추출물 및 천연 식물 복합 추출물을 포함하며, 진주 추출물 및 천연식물 복합 추출물을 1 : 3.5 ~ 5.0 중량비로, 바람직하게는 진주 추출물 및 천연식물 복합 추출물을 1 : 3.8 ~ 4.5 중량비로 포함할 수 있다.In addition, the functional extract includes pearl extract and natural plant complex extract, and the pearl extract and natural plant complex extract are used in a weight ratio of 1:3.5 to 5.0, and preferably, the pearl extract and natural plant complex extract are used in a weight ratio of 1:3.8 to 4.5. It can be included as .
상기 진주(pearl) 추출물의 진주는 조개류의 체내에서 형성되는 구슬 모양의 분비물 덩어리를 의미하며, 진주 100g을 분쇄한 후 2 ~ 4L의 60 ~ 80 부피% 에탄올 수용액을 용매로 사용하여 10 ~ 16시간 정도 가온 환류추출하는 1단계; 환류추출액을 냉침시킨 후, 여과지로 여과하여 여과액을 수득하는 2단계; 수득된 여과액을 감압농축 및 감압 건조로 농축하여 진주 건조 분말을 수득하는 3단계;를 포함하는 공정을 수행하여 제조할 수 있다.The pearl of the pearl extract refers to a bead-shaped mass of secretion formed in the body of a shellfish. After crushing 100 g of pearls, 2 to 4 L of 60 to 80% by volume ethanol aqueous solution is used as a solvent for 10 to 16 hours. Step 1: reflux extraction with moderate heating;
그리고, 상기 천연 식물 복합 추출물은 핑거루트뿌리줄기 추출물(Boesenbergia Pandurata Rhizome Extract), 병풀 추출물, 비타민나무 추출물(Hippophae Rhamnoides Extract), 포트마리골드 추출물(Calendula Officinalis Extract), 녹차 추출물(Camellia Sinensis Leaf Extract), 마트리카리아 추출물(Chamomilla Recutita Extract), 뽕나무잎 추출물(Morus Alba Leaf Extract), 산사나무열매 추출물(Crataegus Pinnatifida Fruit Extract), 페퍼민트 추출물(Mentha Piperita(Peppermint) Extract), 히비스커스꽃 추출물(Hibiscus Sabdariffa Flower Extract) 및 로즈마리 추출물(Rosmarinus Officinalis(Rosemary) Extract)을 포함하며, 바람직하게는 핑거루트뿌리줄기 추출물 100 중량부에 대하여, 병풀 추출물 5.0 ~ 10 중량부, 비타민나무 추출물 0.2 ~ 2.0 중량부, 포트마리골드추출물 0.2 ~ 2.0 중량부, 녹차 추출물 0.2 ~ 2.0 중량부, 마트리카리아 추출물 0.2 ~ 2.0 중량부, 뽕나무잎 추출물 0.05 ~ 0.5 중량부, 산사나무열매 추출물 0.05 ~ 0.5 중량부, 페퍼민트 추출물 0.05 ~ 0.5 중량부, 히비스커스꽃 추출물 0.05 ~ 0.5 중량부 및 로즈마리 추출물 0.05 ~ 0.5 중량부로 포함할 수 있으며, 더욱 바람직하게는 핑거루트뿌리줄기 추출물 100 중량부에 대하여, 병풀 추출물 5.0 ~ 9.0 중량부, 비타민나무 추출물 0.2 ~ 1.5 중량부, 포트마리골드추출물 0.2 ~ 1.5 중량부, 녹차 추출물 0.2 ~ 1.5 중량부, 마트리카리아 추출물 0.2 ~ 1.5 중량부, 뽕나무잎 추출물 0.05 ~ 0.30 중량부, 산사나무열매 추출물 0.05 ~ 0.30 중량부, 페퍼민트 추출물 0.05 ~ 0.30 중량부, 히비스커스꽃 추출물 0.05 ~ 0.30 중량부 및 로즈마리 추출물 0.05 ~ 0.30 중량부를 포함하는 것이 좋다.In addition, the natural plant complex extract includes finger root rhizome extract (Boesenbergia Pandurata Rhizome Extract), Centella asiatica extract, Hippophae Rhamnoides Extract, pot marigold extract (Calendula Officinalis Extract), and green tea extract (Camellia Sinensis Leaf Extract). , Chamomilla Recutita Extract, Morus Alba Leaf Extract, Crataegus Pinnatifida Fruit Extract, Mentha Piperita (Peppermint) Extract, Hibiscus Sabdariffa Flower Extract) and rosemary extract (Rosmarinus Officinalis (Rosemary) Extract), preferably, based on 100 parts by weight of finger root rhizome extract, 5.0 to 10 parts by weight of Centella asiatica extract, 0.2 to 2.0 parts by weight of vitamin tree extract, and Port Marie. Gold extract 0.2 to 2.0 parts by weight, green tea extract 0.2 to 2.0 parts by weight, Matricaria extract 0.2 to 2.0 parts by weight, mulberry leaf extract 0.05 to 0.5 parts by weight, hawthorn fruit extract 0.05 to 0.5 parts by weight, peppermint extract 0.05 to 0.5. Parts by weight, 0.05 to 0.5 parts by weight of hibiscus flower extract and 0.05 to 0.5 parts by weight of rosemary extract, more preferably 5.0 to 9.0 parts by weight of centella asiatica extract, and vitamin tree extract, based on 100 parts by weight of finger root rhizome extract. 0.2 ~ 1.5 parts by weight, port marigold extract 0.2 ~ 1.5 parts by weight, green tea extract 0.2 ~ 1.5 parts by weight, matricaria extract 0.2 ~ 1.5 parts by weight, mulberry leaf extract 0.05 ~ 0.30 parts by weight, hawthorn fruit extract 0.05 ~ 0.30 It is recommended to include 0.05 to 0.30 parts by weight of peppermint extract, 0.05 to 0.30 parts by weight of hibiscus flower extract, and 0.05 to 0.30 parts by weight of rosemary extract.
상기 핑거루트뿌리줄기 추출물은 독성이 제거된 추출물로서, 핑거루트뿌리줄기 에탄올 추출물 또는 핑거루트뿌리줄기 에탄올 추출물의 물 분획물을 사용하는 것이 좋으며, 바람직하게는 독성이 제거된 핑거루트뿌리줄기 에탄올 추출물의 물 분획물을 사용하는 것이 좋으며 이는 하기와 같은 방법을 통해 제조할 수 있다.The finger root rhizome extract is an extract from which toxicity has been removed, and it is better to use the finger root rhizome ethanol extract or the water fraction of the finger root rhizome ethanol extract, preferably the detoxified finger root rhizome ethanol extract. It is recommended to use the water fraction, which can be prepared through the following method.
핑거루트뿌리줄기 에탄올 추출물의 물 분획물은, 핑거루트뿌리줄기 파우더(Powder)을 에탄올(Ethanol) 수용액과 혼합한 후, 교반하여 18 ~ 24시간 동안 15 ~ 30℃ 조건에서 추출공정을 수행하여 에탄올 추출물을 수득하는 1단계; 상기 에탄올 추출물을 필터링한 후, 증류수(Water)를 첨가한 후 진공 상태에서 농축하여 에탄올을 제거된 농축액을 수득하는 2단계; 및 상기 농축액을 DMSO(Dimethyl sulfoxide)로 재용해한 후, 멸균필터로 여과한 다음 동결 건조하는 3단계;를 포함하는 공정을 수행하여 제조할 수 있다.The water fraction of the finger root rhizome ethanol extract is obtained by mixing finger root rhizome powder with an aqueous ethanol solution, stirring, and performing an extraction process at 15 to 30°C for 18 to 24 hours to produce an ethanol extract.
그리고, 물 분획물 제조 공정에서 상기 3단계는 상기 농축액에 디클로로포름(Chloroform)을 넣고 교반하여 방치한 뒤 하층액을 제거하는 3-1단계; 및 상기 하층액 제거 후, 에틸아세테이트(Ethyl Acetate)를 넣고 교반하여 방치한 뒤 하층액을 수득한 후, 수득물을 동결건조하여 분말화시키는 3-2단계;를 수행할 수도 있다.And, in the water fraction production process,
이하에서는 앞서 설명한 제1액 내지 제5액을 포함하는 피부탄력 화장료를 제조하는 방법에 대해 설명한다.Hereinafter, a method of manufacturing a skin elasticity cosmetic containing the first to fifth liquids described above will be described.
본 발명의 화장료는 반응기에 정제수 및 점도조절제를 투입한 후, 교반을 수행하여 제1액을 제조하는 1단계; 제1액이 제조된 반응기에 제2액을 투입한 후, 교반을 수행하는 2단계; 2단계를 수행한 반응기에 제3액을 투입한 후, 교반을 수행하는 3단계; 3단계를 수행한 반응기에 제4액을 투입한 후, 교반을 수행하는 4단계; 4단계를 수행한 반응기에 pH 조절제를 투입한 후, 교반을 수행하는 5단계; 5단계를 수행한 반응기에 제5액을 투입한 후, 교반을 수행하는 6단계;를 수행하여 제조할 수 있다.The cosmetic of the present invention includes the first step of preparing a first liquid by adding purified water and a viscosity modifier to a reactor and then performing stirring; Step 2 of adding the second liquid to the reactor in which the first liquid was prepared and then performing stirring; Step 3 of adding the third liquid to the reactor that performed
또한, 6단계를 수행한 후, 6단계를 수행한 혼합액을 여과 및 탈포하는 7단계; 및 7단계를 수행한 혼합액을 숙성시키는 8단계;를 포함하는 공정을 더 수행하여 제조할 수도 있다.In addition, after performing step 6, step 7 of filtering and degassing the mixed solution obtained from step 6; And it can also be manufactured by further performing a
상기 1단계의 교반은 60 ~ 80℃ 및 교반속도 3000 ~ 4000rpm의 조건으로, 바람직하게는 65 ~ 75℃ 및 교반속도 3200 ~ 3800rpm 조건 하에서, 30 ~ 50분 동안, 바람직하게는 35 ~ 45분 동안 수행하는 것이 좋다. 이때, 교반시 온도가 60℃ 미만이거나, 교반속도가 3000rpm 미만이면 점도조절제가 정제수에 완전히 용해되지 않아서 교반시간이 길어지는 문제가 있을 수 있고, 교반시 온도가 80℃를 초과하는 것은 비경제적이며, 교반속도가 4000rpm을 초과하면 거품이 발생할 수 있으므로 상기 조건 하에서 교반을 수행하는 것이 좋다.The stirring in
상기 2단계의 교반은 45 ~ 60℃ 및 교반속도 2000 ~ 3000rpm의 조건으로, 바람직하게는 45 ~ 55℃ 및 교반속도 2200 ~ 2700rpm 조건 하에서, 20 ~ 40분 동안, 바람직하게는 20 ~ 35분 동안 수행하는 것이 좋다.The second stage of stirring is performed under the conditions of 45 to 60°C and a stirring speed of 2000 to 3000 rpm, preferably for 20 to 40 minutes, preferably for 20 to 35 minutes, under the conditions of 45 to 55°C and a stirring speed of 2200 to 2700 rpm. It is good to practice.
또한, 상기 3단계의 교반은 35 ~ 45℃ 및 교반속도 1500 ~ 2500rpm의 조건으로, 바람직하게는 35 ~ 45℃ 및 교반속도 1800 ~ 2300rpm 조건 하에서, 20 ~ 40분 동안, 바람직하게는 20 ~ 35분 동안 수행하는 것이 좋다.In addition, the third step of stirring is performed at 35 to 45°C and a stirring speed of 1500 to 2500 rpm, preferably for 20 to 40 minutes, preferably at 35 to 45°C and a stirring speed of 1800 to 2300 rpm. It is recommended to practice for minutes.
또한, 상기 4단계의 교반은 35 ~ 45℃ 및 교반속도 1500 ~ 2500rpm의 조건으로, 바람직하게는 35 ~ 45℃ 및 교반속도 1800 ~ 2300rpm 조건 하에서, 20 ~ 40분 동안, 바람직하게는 20 ~ 35분 동안 수행하는 것이 좋다.In addition, the stirring in the fourth step is performed at 35 to 45°C and a stirring speed of 1500 to 2500 rpm, preferably for 20 to 40 minutes, preferably at 35 to 45°C and a stirring speed of 1800 to 2300 rpm. It is recommended to practice for minutes.
그리고, 5단계의 교반은 pH 조절제를 투입한 후, 15 ~ 30℃ 및 교반속도 2000 ~ 3000rpm의 조건으로, 바람직하게는 20 ~ 30℃ 및 교반속도 2200 ~ 2700rpm 조건 하에서, 20 ~ 40분 동안, 바람직하게는 20 ~ 35분 동안 수행하는 것이 좋다. 그리고, 상기 pH 조절제의 바람직한 일례로는 알지닌(arginine)을 사용할 수 있으며, 제1액 100 중량부에 대하여, 0.10 ~ 0.50 중량부, 바람직하게는 0.15 ~ 0.35 중량부 정도로 투입하는 것이 적절하다.In addition, the fifth stage of stirring is performed after adding the pH regulator, at a temperature of 15 to 30°C and a stirring speed of 2000 to 3000 rpm, preferably at a temperature of 20 to 30°C and a stirring speed of 2200 to 2700 rpm, for 20 to 40 minutes. Preferably it is performed for 20 to 35 minutes. In addition, arginine can be used as a preferred example of the pH adjuster, and it is appropriate to add 0.10 to 0.50 parts by weight, preferably 0.15 to 0.35 parts by weight, based on 100 parts by weight of the first liquid.
또한, 6단계의 교반은 15 ~ 30℃ 및 교반속도 1500 ~ 2500rpm의 조건으로, 바람직하게는 15 ~ 30℃ 및 교반속도 1800 ~ 2300rpm 조건 하에서, 20 ~ 40분 동안, 바람직하게는 20 ~ 35분 동안 수행하는 것이 좋다.In addition, the 6th stage of stirring is performed under the conditions of 15 to 30°C and a stirring speed of 1500 to 2500 rpm, preferably for 20 to 40 minutes, preferably 20 to 35 minutes, under the conditions of 15 to 30°C and a stirring speed of 1800 to 2300 rpm. It is best to practice it for a while.
앞서 설명한 조성 및 방법으로 제조한 본 발명의 피부탄력 개선 화장료는 당업계에서 통상적으로 제조되는 어떠한 제형의 화장품으로 제조될 수 있으며, 피부과학적으로 허용 가능한 매질 또는 기제를 함유함으로써 피부과학 분야에서 통상적으로 사용되는 국소적용 또는 전신 적용할 수 있는 보조제 형태로 제조될 수 있다.The skin elasticity improvement cosmetic of the present invention manufactured using the composition and method described above can be manufactured into any type of cosmetic product commonly manufactured in the art, and contains a dermatologically acceptable medium or base, so that it is commonly used in the field of dermatology. It can be formulated as an adjuvant for topical or systemic application.
또한, 바람직하게는 앰플 제형의 화장품으로 제조할 수 있으며, 상기 앰플 제형 화장품은 점도 12,000 ~ 20,000cP 및 pH 6.0 ~ 7.0일 수 있다.Additionally, it can preferably be manufactured into an ampoule formulation cosmetics, and the ampoule formulation cosmetics may have a viscosity of 12,000 to 20,000 cP and a pH of 6.0 to 7.0.
이상에서 본 발명에 대하여 구현예를 중심으로 설명하였으나 이는 단지 예시일 뿐 본 발명의 구현예를 한정하는 것이 아니며, 본 발명의 실시예가 속하는 분야의 통상의 지식을 가진 자라면 본 발명의 본질적인 특성을 벗어나지 않는 범위에서 이상에 예시되지 않은 여러 가지의 변형과 응용이 가능함을 알 수 있을 것이다. 예를 들어, 본 발명의 구현예에 구체적으로 나타난 각 구성 요소는 변형하여 실시할 수 있는 것이다. 그리고 이러한 변형과 응용에 관계된 차이점들은 첨부된 청구 범위에서 규정하는 본 발명의 범위에 포함되는 것으로 해석되어야 할 것이다.Although the present invention has been described above with a focus on embodiments, this is only an example and does not limit the embodiments of the present invention, and those skilled in the art will be able to understand the essential characteristics of the present invention. It can be seen that various modifications and applications not exemplified above are possible without departing from the scope. For example, each component specifically shown in the embodiments of the present invention can be modified and implemented. And these variations and differences in application should be construed as being included in the scope of the present invention as defined in the appended claims.
[실시예][Example]
준비예 1 : 핑거루트뿌리줄기 추출물의 제조Preparation Example 1: Preparation of finger root rhizome extract
(1) 핑거루트뿌리줄기 분말 5g을 취한 후, 용매별로 핵산(hexane), 디클로로포름(Dichloroform), 에틸아세테이트(ethyl acetate), 에탄올(ethanol), 메탄올(methanol) 및 물(water) 100ml을 각각 넣고 셰이커(shaker)를 이용하여 24시간 동안 25℃에서 추출하여 추출액을 각각 수득하였다. 다음으로, 수득한 추출액을 필터(Whatman No.2 filter paper)를 이용하여 필터링한 후 용매별 추출물을 진공 상태에서 농축하였다. 농축액을 DMSO(dimethyl sulfoxide, 다이메틸 설폭사이드)로 재용해한 후 0.22um 멸균필터로 여과한 후, -20℃에서 냉동 보관하였다. 그리고, 물 추출물은 필터링한 후 동결건조하여 파우더를 50 부피% DMSO에 재용해한 후 멸균필터로 여과하여 사용하였다.(1) After taking 5g of finger root rhizome powder, add 100ml of hexane, dichloroform, ethyl acetate, ethanol, methanol, and water for each solvent. and extracted at 25°C for 24 hours using a shaker to obtain each extract. Next, the obtained extract was filtered using a filter (Whatman No.2 filter paper), and then the extract for each solvent was concentrated in vacuum. The concentrate was re-dissolved in DMSO (dimethyl sulfoxide), filtered through a 0.22um sterilizing filter, and stored frozen at -20°C. Then, the water extract was filtered, lyophilized, and the powder was redissolved in 50% by volume DMSO and then filtered through a sterilizing filter for use.
디클로로포름, 에틸아세테이트, 에탄올 및 메탄올 용매 추출물은 연한 노란색을 띄었고, 헥산 추출물은 무색을 띄었다.Dichloroform, ethyl acetate, ethanol, and methanol solvent extracts were light yellow, and hexane extracts were colorless.
(2) 지표 성분 분석(2) Index component analysis
핑거루트뿌리줄기 추출물을 같은 농도로 분취하여 HLPC 시료로 준비하였다.Finger root rhizome extract was aliquoted at the same concentration and prepared as an HLPC sample.
핑거루트 추출물의 지표성분 판투라틴(Panduratin) A와 용매별 추출물의 HPLC 크래마토그램(chromatogram)을 비교하여 추출물 내 판두라틴 A 함량을 분석하였다. 판두라틴 A의 화학구조는 하기 화학식 1과 같다.The content of panduratin A in the extract was analyzed by comparing the HPLC chromatogram of the extract by solvent with panduratin A, an indicator component of the finger root extract. The chemical structure of panduratin A is shown in
[화학식 1][Formula 1]
분석 방법은 정량성 작성을 위해 판두라틴 A는 메탄올에 녹여 단계적으로 희석하여 시료 조제하였으며, HPLC측정 조건은 하기 표 1과 같으며, 분석방법의 유효화(validation)은 하기 표 2와 같다.For the analysis method, panduratin A was dissolved in methanol and diluted stepwise to prepare the sample for quantitative purposes. The HPLC measurement conditions are shown in Table 1 below, and the validation of the analysis method is shown in Table 2 below.
(Mobile phase)mobile phase
(Mobile phase)
그리고, 용매별 추출물 내 판두라틴 A 함량 측정 결과는 하기 표 3에 나타내었다.And, the results of measuring the panduratin A content in the extract by solvent are shown in Table 3 below.
상기 표 3의 측정 결과를 살펴보면, 모든 추출 용매에서 29.3분에 지표물질 판두라틴 A가 검출이 되었고, 에틸아세테이트(4.042), 에탄올(4.030), 메탄올(3.663) 순으로 높은 농도의 판두라틴 A를 함유한 것을 확인할 수 있었다.Looking at the measurement results in Table 3, the indicator panduratin A was detected in all extraction solvents at 29.3 minutes, and the highest concentrations of panduratin A were detected in the following order: ethyl acetate (4.042), ethanol (4.030), and methanol (3.663). It was confirmed that it contained
실험예 1 : 핑거루트뿌리줄기 추출물의 독성 실험Experimental Example 1: Toxicity test of finger root rhizome extract
준비예 1에서 제조한 핵산 추출물(H), 디클로로포름 추출물(Ch), 에틸아세테이트 추출물(EA), 에탄올 추출물(Et), 메탄올 추출물(Me) 및 물 추출물 각각에 대한 독성 실험을 수행하였고, 그 결과를 도 1의 A ~ C에 나타내었다. 시험에 사용한 AsA는 양성대조군(positive control)으로 아스코르브산(ascorbic acid, Vit.C)을 표기한 것이다.Toxicity tests were performed on each of the nucleic acid extract (H), dichloroform extract (Ch), ethyl acetate extract (EA), ethanol extract (Et), methanol extract (Me), and water extract prepared in Preparation Example 1. The results are shown in Figure 1 A to C. AsA used in the test is a positive control and is indicated as ascorbic acid (Vit.C).
핵산(hexane, H), 디클로로포름(dichloroform, Ch), 에틸아세테이트(ethyl acetate, EA), 에탄올(ethanol, Et), 메탄올(methanol, Me) 및 물(water, W)을 각각 용매로 한 추출물을 0.1, 0.5, 1, 5μg/ml 농도로 피부세포 Hs68를 처리한 결과로서, 물 추출물을 제외한 나머지 추출물들 5μg/ml에서 모두 높은 독성이 나타났다.Extracts using nucleic acid (hexane, H), dichloroform (Ch), ethyl acetate (EA), ethanol (Et), methanol (Me), and water (W) as solvents, respectively. As a result of treating skin cells Hs68 at concentrations of 0.1, 0.5, 1, and 5μg/ml, all extracts except the water extract showed high toxicity at 5μg/ml.
실험예 2 : 핑거루트뿌리줄기 추출물의 UVB 자극에 대한 세포 보호 효과 및 콜라게나아제 생성 저해 실험Experimental Example 2: Cell protection effect and collagenase production inhibition experiment of finger root rhizome extract against UVB stimulation
(1) 세포 보호 효과(1) Cell protective effect
UVB 자극에 대한 세포 보호효과를 측정하기 위해 세포독성을 측정할 때와 같은 농도로 처리하여 용매별 핑거루트뿌리줄기 추출물의 UVB 자극에 대한 세포 보호효과를 측정한 실험 결과를 도 2의 A ~ C에 나타내었다. 도 2에 나타난 바와 같이, 에탄올과 메탄올을 제외한 나머지 시료에선 세포 보호효과가 뚜렷하게 나타나지 않았다.In order to measure the cytoprotective effect against UVB stimulation, the results of an experiment measuring the cytoprotective effect against UVB stimulation of the finger root rhizome extract for each solvent were treated at the same concentration as when measuring cytotoxicity, and the results are shown in Figures 2A to C. shown in As shown in Figure 2, the cell protection effect was not clearly observed in the remaining samples except ethanol and methanol.
또한, 도 3의 A 및 B는 용매별 핑거루트뿌리줄기 추출물의 UVB 자극에 대한 세포 보호효과를 대비하기 위하여 0.5 및 1μg/ml의 농도에 대하여 실험한 결과를 함께 나타낸 그래프이다. 도 3에 도시된 바와 같이, UVB자극에 대한 세포 보호효과 실험결과, 에탄올 추출물에서 효과가 가장 좋게 나타났으며, 1μg/ml보다 0.5μg/ml에서 보호효과가 유의적으로 증가하였으며, 핑거루트뿌리줄기 에탄올 추출물의 UVB에 대한 세포 보호효과가 가장 높게 나타났다.In addition, Figures A and B of Figure 3 are graphs showing the results of experiments at concentrations of 0.5 and 1 μg/ml to compare the cell protection effect against UVB stimulation of finger root rhizome extracts for each solvent. As shown in Figure 3, as a result of the cell protection effect test against UVB stimulation, the ethanol extract showed the best effect, and the protective effect significantly increased at 0.5 μg/ml compared to 1 μg/ml, and the finger root The stem ethanol extract showed the highest cell protection effect against UVB.
(2) 콜라게나아제 생성 저해 실험(2) Collagenase production inhibition experiment
핑거루트뿌리줄기 에탄올 추출물의 0.5μg/ml, 1.0μg/ml, 2.5μg/ml에서의 콜라게나아제 생성((Pro-collagen synthesis) 저해 효능 시험을 수행하였고, 결과를 하기 표 4에 나타내었다. 양성대조군은 TFG-베타1 100ng/ml이며, 대조군은 에탄물 추출물 미처리군이다.A test was performed on the efficacy of the ethanol extract of the finger root rhizome to inhibit collagenase production (Pro-collagen synthesis) at 0.5 μg/ml, 1.0 μg/ml, and 2.5 μg/ml, and the results are shown in Table 4 below. The positive control group was 100ng/ml of TFG-beta1, and the control group was the untreated group with ethane water extract.
상기 표 4의 콜라게나아제 생성 저해 실험을 통해, 핑거루트뿌리줄기 에탄올 추출물이 콜라게나아제 활성 억제 효과가 있고, 이를 통해 피부 주름 개선 활성 효과가 있음을 확인할 수 있었다.Through the collagenase production inhibition experiment shown in Table 4 above, it was confirmed that the ethanol extract of finger root rhizome has an effect of inhibiting collagenase activity, and through this, has an effect of improving skin wrinkles.
준비예 2 : 핑거루트뿌리줄기 추출물의 분획물 제조Preparation Example 2: Preparation of fractions of finger root rhizome extract
핑거루트뿌리줄기 분말 100g을 취하여 에탄올 1L를 넣고 셰이커를 이용하여 24시간 동안 25℃에서 추출하였다. 필터(Whatman No.2 filter paper)를 이용하여 필터링하여 핑거루트뿌리줄기 에탄올 추출물을 수득하였다. 핑거루트뿌리줄기 에탄올 추출물 1L 중 100ml를 취하여 증류수를 200ml 첨가하였다.Take 100g of finger root rhizome powder, add 1L of ethanol, and extract at 25°C for 24 hours using a shaker. An ethanol extract of finger root rhizome was obtained by filtering using a filter (Whatman No.2 filter paper). 100ml of 1L of finger root rhizome ethanol extract was taken and 200ml of distilled water was added.
핑거루트뿌리줄기 에탄올 추출물과 증류수의 혼합물을 진공 상태에서 농축하여 에탄올을 모두 날린 후 분액 깔대기에 옮겼다. 여기에 디클로로포름 총 2L를 넣고 충분히 셰이킹(shaking)하여 방치한 뒤 분리시켰고 하층액을 수집하여 농축하였다.The mixture of finger root rhizome ethanol extract and distilled water was concentrated under vacuum, all ethanol was removed, and then transferred to a separatory funnel. A total of 2L of dichloroform was added here, shaken sufficiently, left to stand, and then separated, and the lower layer was collected and concentrated.
디클로로포름 분획 후에는 에틸아세테이트 총 1L를 넣고 충분히 셰이킹하여 방치한 뒤 분리하여 상층액을 수집하여 농축하였다. 에틸아세테이트를 제거하고 남은 물층은 동결건조하여 파우더 형태로 만들었다. 농축액과 파우더는 모두 DMSO로 재용해한 후 이어서 0.22um 멸균필터로 여과하고, 분석 전까지 -20℃에서 보관하여, 핑거루트뿌리줄기 에탄올 추출물에 대한 에탄올 분획물, 디클로로포름 분획물, 에틸아세테이트 분획 및 물 분획물을 각각 수득하였다.After dichloroform fractionation, a total of 1L of ethyl acetate was added, shaken sufficiently, left to stand, separated, and the supernatant was collected and concentrated. Ethyl acetate was removed, and the remaining water layer was freeze-dried to form a powder. Both the concentrate and powder were re-dissolved in DMSO, then filtered through a 0.22um sterilizing filter, and stored at -20°C until analysis. The ethanol fraction, dichloroform fraction, ethyl acetate fraction, and water fraction for the ethanol extract of finger root rhizome were analyzed. were obtained respectively.
실험예 3 : 핑거루트뿌리줄기 에탄올 추출 분획물의 세포 독성 실험Experimental Example 3: Cytotoxicity test of ethanol extracted fraction of finger root rhizome
준비예 2에서 수득한 에탄올 추출 분획물에 대한 세포독성을 실시하였으며, 세포배양 및 세포독성 실험은 다음과 같다.Cytotoxicity was performed on the ethanol-extracted fraction obtained in Preparation Example 2, and cell culture and cytotoxicity experiments were as follows.
세포독성 실험에 사용된 인체 피부 섬유아세포주인 Hs68세포는 ATCC(American Type Culture Collection, Manassas, VA, USA)에서 구입하였다. 10% FBS와 페니실린(penicillin, 100unit/ml), 스트렙토마이신(streptomycin, 50μg/ml)이 함유된 DMEM(Dulbecco’s Modified Eagle’s Medium)배지를 사용하여 37℃, 5% 이산화탄소(CO2) 및 95% 습공기(humid air)로 조절된 배양기(Thermo Scientific, Tewksbury, MA, USA)에서 배양하였다. Hs68세포를 96-well plate에 1.0×104cells/well의 농도로 분주하여 24시간 배양 후 배지를 샘플이 함유되고, FBS가 함유되지 않은 배지로 교체하였다. 24시간 시료 처리 후 MTT(1 mg/ml)용액 20uL를 각 well에 첨가하고, 2시간 동안 배양하였다. 마지막으로 상층액을 제거하고, 생존세포에서 생성된 청색 포르마잔(formazan)결정을 DMSO로 가용화 시켜 Microplate reader(BioTek, Inc., Winooski, VT,USA)를 사용하여 550nm에서의 흡광도를 측정하였다. 시료처리 시에는 DMSO의 최종 농도가 0.1%(v/v) 미만이 되도록 샘플을 배지로 희석하여 사용하였다.Hs68 cells, a human skin fibroblast cell line used in cytotoxicity experiments, were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA). DMEM (Dulbecco's Modified Eagle's Medium) containing 10% FBS, penicillin (100 units/ml), and streptomycin (50 μg/ml) was used at 37°C, 5% carbon dioxide (CO 2 ), and 95% humid air. Cultured in an incubator (Thermo Scientific, Tewksbury, MA, USA) controlled by (humid air). Hs68 cells were distributed in a 96-well plate at a concentration of 1.0 After sample treatment for 24 hours, 20uL of MTT (1 mg/ml) solution was added to each well and incubated for 2 hours. Finally, the supernatant was removed, and the blue formazan crystals generated from the viable cells were solubilized with DMSO and the absorbance at 550 nm was measured using a Microplate reader (BioTek, Inc., Winooski, VT, USA). When processing samples, the samples were diluted with medium so that the final concentration of DMSO was less than 0.1% (v/v).
각 분획물의 농도에 따른 세포독성을 평가하기 위해 hs68세포에 0.1, 0.5, 1, 5μg/ml 를 처리하였다. 농도 별로 처리한 결과, 도 4의 A 및 B에 나타낸 바와 같이, 물 분획물을 제외한 나머지 분획물의 5μg/ml에서 모두 세포독성을 나타냈다.To evaluate cytotoxicity according to the concentration of each fraction, hs68 cells were treated with 0.1, 0.5, 1, and 5 μg/ml. As a result of treatment according to concentration, as shown in Figure 4 A and B, all fractions except the water fraction showed cytotoxicity at 5 μg/ml.
실험예 4 : 핑거루트뿌리줄기 에탄올 추출 분획물의 UVB 자극에 대한 세포 보호 효과 실험Experimental Example 4: Cell protection effect test on UVB stimulation of ethanol-extracted fraction of finger root rhizome
Hs68세포를 96-well plate에 1.0×104 cells/well의 농도로 분주하여 24시간 동안 배양한 후, 각 well에 FBS가 없는 배지로 샘플을 희석한 후 처리하여 24시간 동안 배양하였다.Hs68 cells were distributed in a 96-well plate at a concentration of 1.0
그 후 UVB 램프(Sankyo Denki Lamps, GL20SE, Marine, Japan)를 이용하여 UVB(30mJ/cm2)를 조사하였고, UV LIGHT METER(LT Lutron, UV-340A, Taiwan)를 사용하여 자외선 강도를 모니터링 하였다. 모든 UVB 조사는 96-well plate에 부착된 세포에 PBS를 얇게 도포한 후 수행하였다. 조사 후 FBS가 없는 배지에서 샘플을 희석하여 24시간 동안 세포에 처리하였다. 대조군은 UVB 조사 없이 동일한 조건으로 진행되었다.Afterwards, UVB (30mJ/cm 2 ) was irradiated using a UVB lamp (Sankyo Denki Lamps, GL20SE, Marine, Japan), and the intensity of ultraviolet rays was monitored using a UV LIGHT METER (LT Lutron, UV-340A, Taiwan). . All UVB irradiation was performed after applying a thin layer of PBS to cells attached to a 96-well plate. After irradiation, samples were diluted in FBS-free medium and treated with cells for 24 hours. The control group was conducted under the same conditions without UVB irradiation.
에탄올 추출 분획물 각각에 대한 UVB조사에 대한 세포 보호효과를 평가하기 위하여 세포에 UVB조사 전 후에 각 용매별 추출물을 0.1, 0.5, 1, 5μg/ml 농도로 처리하였다. 그 결과, 도 5의 A 및 B에 나타낸 바와 같이 물 분획물만이 5μg/ml까지 독성 없이 보호효과 활성이 유지되었다.To evaluate the cell protection effect against UVB irradiation for each of the ethanol-extracted fractions, cells were treated with extracts from each solvent at concentrations of 0.1, 0.5, 1, and 5 μg/ml before and after UVB irradiation. As a result, as shown in Figure 5A and B, only the water fraction maintained the protective effect without toxicity up to 5 μg/ml.
핑거루트뿌리줄기 에탄올 추출물의 물 분획물을 선택하여 농도별(1, 5, 25, 50μg/ml) 세포독성과 UVB에 대한 세포 보호효과를 측정하였고, 그 결과를 도 6에 나타내었다. 세포독성 실험결과인 도 6의 A를 살펴보면, 세포독성의 경우 25μg/ml까지 세포독성을 나타내지 않았으나, 50μg/ml에서 세포 생존율이 86%로 감소하여 독성을 나타내는 것으로 판단하였다. 한편, 세포 보호효과의 경우, 세포보호 실험결과인 도 6의 B에 나타난 바와 같이 5μg/ml, 25μg/ml에서 세포 보호효과를 나타내었다.The water fraction of the ethanol extract of finger root rhizome was selected to measure cytotoxicity and cytoprotective effect against UVB at different concentrations (1, 5, 25, 50 μg/ml), and the results are shown in Figure 6. Looking at A in Figure 6, which is the cytotoxicity test result, in the case of cytotoxicity, it did not show cytotoxicity up to 25μg/ml, but the cell viability decreased to 86% at 50μg/ml, which was judged to indicate toxicity. Meanwhile, in the case of the cell protection effect, as shown in B of Figure 6, which is the result of the cell protection experiment, the cell protection effect was shown at 5 μg/ml and 25 μg/ml.
위 시험결과, 핑거루트뿌리줄기 에탄올 추출물의 물 분획물 25μg/ml에서 세포생존율이 약간 감소하는 경향을 보였으므로, 샘플 처리시 농도의존적으로 증가하는 이상적인 결과를 도출하기 위하여 최고농도를 20μg/ml으로 설정하였다.The above test results showed a slight decrease in cell viability at 25 μg/ml of the water fraction of the ethanol extract of finger root rhizomes, so the highest concentration was set at 20 μg/ml to obtain ideal results that increase in a concentration-dependent manner when processing the sample. did.
핑거루트뿌리줄기 에탄올 추출물의 물 분획물 1~20μg/ml 의 세포독성 및 UVB에 대한 세포 보호효과를 측정한 결과, 20μg/ml까지 독성을 나타내지 않았고(도 7의 A 참조), UVB에 의해 감소된 세포생존율을 농도의존적으로 증가시켰다(도 7의 B 참조).As a result of measuring the cytotoxicity and cytoprotective effect against UVB of 1 to 20 μg/ml of the water fraction of the ethanol extract of finger root rhizome, no toxicity was observed up to 20 μg/ml (see A in Figure 7), and the cytotoxicity was reduced by UVB. Cell viability increased in a concentration-dependent manner (see B in Figure 7).
실험예 5 : 핑거루트뿌리줄기 에탄올 추출물의 물 분획물에 대한 세포 내 콜라겐 영향 평가Experimental Example 5: Evaluation of intracellular collagen effect on water fraction of finger root rhizome ethanol extract
UVB 조사는 세포의 콜라겐 생성을 감소시킨다. 따라서 핑거루트 추출물의 물 분획물이 세포 내 콜라겐 양에 미치는 영향을 측정하였다. 실험방법은 하기와 같다.UVB irradiation reduces collagen production in cells. Therefore, the effect of the water fraction of finger root extract on the amount of collagen in cells was measured. The experimental method is as follows.
(1) MMP-1, MMP-3 및 수용성 콜라겐 생성량 측정(1) Measurement of MMP-1, MMP-3, and soluble collagen production
UVB 조사에 의해 합성이 증가되는 MMP-1과 MMP-3의 측정은 human MMP-1, MMP-3 ELISA kit(Merck & Co. Inc., Whitehouse Station, NJ, USA)를 이용하여 enzyme-linked immunosorbent assay 방법으로 배지 중의 pro-MMP-1과 MMP-3의 생성량을 측정하였다. UVB 조사 후 수용성 콜라겐 생성량은 SircolTM soluble collagen assay kit를 사용하여 측정하였다. 세포를 배양한 배지를 수집하여 Sirco dye reagent와 혼합, 반응하여 원심분리 후 차가운 산-염 세척액(acid-salt washing reagent)을 침전물에 첨가하여 혼합하였다. 혼합물을 원심분리한 후 침전물을 알칼리 시약(alkali reagent)를 사용하여 용해시키고, 555nm에서 흡광도를 측정하였고 실험결과를 도 8 의 A에 나타내었다.MMP-1 and MMP-3, the synthesis of which is increased by UVB irradiation, were measured using an enzyme-linked immunosorbent human MMP-1, MMP-3 ELISA kit (Merck & Co. Inc., Whitehouse Station, NJ, USA). The production amounts of pro-MMP-1 and MMP-3 in the medium were measured using the assay method. The amount of soluble collagen produced after UVB irradiation was measured using the SircolTM soluble collagen assay kit. The medium in which the cells were cultured was collected, mixed with Sirco dye reagent, reacted, centrifuged, and then cold acid-salt washing reagent was added to the precipitate and mixed. After centrifuging the mixture, the precipitate was dissolved using an alkaline reagent, and the absorbance was measured at 555 nm, and the experimental results are shown in A of Figure 8.
도 8의 A를 살펴보면, UVB는 세포 내 콜라겐 양을 감소시켰고, 1μg/ml부터 20μg/ml까지 물 분획물 처리시 그 농도가 증가함에 따라 콜라겐 수준이 농도의존적으로 증가하였다.Looking at A of Figure 8, UVB decreased the amount of collagen in cells, and the level of collagen increased in a concentration-dependent manner as the concentration increased when treating the water fraction from 1 μg/ml to 20 μg/ml.
이때, UVB 조사는 피부에 가장 많이 존재하는 단백질인 Type 1 콜라겐을 분해하는 효소인 MMP-1(Matrix MetalloProtease)의 생성을 증가시켜 콜라겐의 분해를 촉진한다. 따라서 MMP-1 생성에 미치는 핑거루트 추출물의 물 분획물의 영향을 전술한 방법으로 평가하였고 그 결과를 도 8의 B에 나타내었다. UVB조사시 MMP-1 생성이 증가하였고, 물 분획물 처리시 1μg/ml부터 20μg/ml까지 농도가 증가함에 따라 MMP-1생성이 감소하였다.At this time, UVB irradiation promotes collagen decomposition by increasing the production of MMP-1 (Matrix MetalloProtease), an enzyme that decomposes
또한, MMP-3는 MMP-1을 활성화시켜 콜라겐의 분해를 촉진하므로, MMP-1과 동일한 방법으로 MMP-3 생성량을 측정하였으며, 실험결과를 도 8의 C에 나타내었다. UVB조사시 MMP-3 생성이 증가하였고, 물 분획물 처리시 1μg/ml부터 20μg/ml까지 농도가 증가함에 따라 MMP-3생성이 감소하였다.In addition, since MMP-3 promotes the decomposition of collagen by activating MMP-1, the amount of MMP-3 produced was measured in the same manner as for MMP-1, and the experimental results are shown in Figure 8C. Upon UVB irradiation, MMP-3 production increased, and when treating the water fraction, MMP-3 production decreased as the concentration increased from 1 μg/ml to 20 μg/ml.
실험예 6 : 핑거루트뿌리줄기 에탄올 추출물의 물 분획물에 대한 세포 내 항산화 영향 평가Experimental Example 6: Evaluation of intracellular antioxidant effect of water fraction of finger root rhizome ethanol extract
UVB 조사는 세포 내 Reactive oxygen species(ROS, 활성산소종)의 생성을 촉진시킨다. 이러한 비정상적인 활성산소종의 증가는 산화적 스트레스를 유발하고 진피 섬유아세포(fibroblast)에서 MMPs을 유도하여 피부노화를 촉진한다. 따라서 핑거루트뿌리줄기 추출물의 물 분획물의 ROS 생성에 미치는 영향을 평가하였다. 실험방법은 하기와 같다.UVB irradiation promotes the production of reactive oxygen species (ROS) within cells. This abnormal increase in reactive oxygen species causes oxidative stress and induces MMPs in dermal fibroblasts, thereby promoting skin aging. Therefore, the effect of the water fraction of finger root rhizome extract on ROS production was evaluated. The experimental method is as follows.
(1) ROS 생성 측정(1) Measurement of ROS production
활성산소(Reactive Oxygen Species, ROS) 생성을 측정하기 위해 Hs68 세포에 샘플을 24시간 동안 전처리하고, PBS로 세척한 후 세포를 UVB(30mJ/cm2)로 조사하였다. UVB 조사 후 세포에 샘플을 30분간 처리한 후 25uM의 DCFH-DA로 염색하였다. 세포 내 ROS 생성에 해당하는 형광 강도는 485nm의 여기 파장 및 530nm의 방출 파장에서 2시간 동안 fluorescent spectrophotometer(Perkin-Elmer, Norwalk, CT, USA)로 측정하였다.To measure the production of reactive oxygen species (ROS), Hs68 cells were pretreated with samples for 24 hours, washed with PBS, and then cells were irradiated with UVB (30mJ/cm2). After UVB irradiation, the cells were treated with samples for 30 minutes and then stained with 25uM DCFH-DA. The fluorescence intensity corresponding to intracellular ROS production was measured with a fluorescent spectrophotometer (Perkin-Elmer, Norwalk, CT, USA) at an excitation wavelength of 485 nm and an emission wavelength of 530 nm for 2 hours.
핑거루트 에탄올 추출물의 물 분획물 1~20μg/ml 의 농도에 따른 ROS 활성산소(Reactive Oxygen Species, ROS) 생성을 측정하기 위한 형광 강도 측정 그래프를 도 9에 나타내었다.A fluorescence intensity measurement graph for measuring the production of ROS reactive oxygen species (ROS) according to the concentration of 1 to 20 μg/ml of the water fraction of the finger root ethanol extract is shown in Figure 9.
도 9를 살펴보면, UVB조사는 세포 내 ROS의 생성을 증가시켰으며, 물 분획물 처리시 농도의존적으로 ROS 생성을 감소시킴을 확인할 수 있었다.Looking at Figure 9, it was confirmed that UVB irradiation increased the production of ROS in cells, and that treatment of the water fraction reduced ROS production in a concentration-dependent manner.
실시예 1 : 앰플 제형의 피부탄력 개선 화장료(화장품)의 제조Example 1: Preparation of ampoule-type skin elasticity improving cosmetics (cosmetics)
반응기에 정제수 및 아크릴레이트/C10-30알킬아크릴레이트크로스폴리머(Carbopol ETD-2020) 0.13 중량% 및 정제수 99.87 중량%를 투입한 후, 70℃ 하에서 3,500rpm 속도로 40분간 교반하여 제1액을 제조하였다.Purified water and acrylate/C 10-30 alkyl acrylate crosspolymer (Carbopol) were added to the reactor. After adding 0.13% by weight of ETD-2020) and 99.87% by weight of purified water, the first solution was prepared by stirring at 3,500 rpm at 70°C for 40 minutes.
잔탄검 및 보습제를 포함하는 제2액을 준비한 후, 제1액 100 중량부에 대하여 제2액 8.13 중량부로 제1액이 제조된 반응기에 투입한 후, 50℃ 하에서 2,500rpm 속도로 30분간 교반을 수행하였다. 이때, 제2액의 조성은 하기 표 5과 같다.After preparing a second liquid containing xanthan gum and a humectant, 8.13 parts by weight of the second liquid relative to 100 parts by weight of the first liquid was added to the reactor in which the first liquid was prepared, and then stirred for 30 minutes at a speed of 2,500 rpm at 50°C. was carried out. At this time, the composition of the second liquid is shown in Table 5 below.
다음으로, 피부 컨디셔닝제, 습윤제 및 용매를 포함하는 제3액을 제조한 후, 제1액 100 중량부에 대하여 제3액 14.17 중량부로 제2액이 혼합된 반응기에 투입한 후, 40℃ 하에서 2,000rpm 속도로 30분간 교반을 수행하였다. 이때, 제3액 및 제4액의 조성은 하기 표 6와 같다.Next, after preparing a third liquid containing a skin conditioning agent, a humectant, and a solvent, 14.17 parts by weight of the third liquid based on 100 parts by weight of the first liquid was added to the reactor in which the second liquid was mixed, and then heated at 40°C. Stirring was performed at 2,000 rpm for 30 minutes. At this time, the compositions of the third and fourth liquids are shown in Table 6 below.
다음으로, 유화제, 향료 및 용매를 포함하는 제4액을 제조한 후, 제1액 100 중량부에 대하여 제3액 0.40 중량부로 제3액이 혼합된 반응기에 투입한 후, 40℃ 하에서 2,000rpm 속도로 30분간 교반을 수행하였다. 이때, 제4액의 조성은 하기 표 6와 같다.Next, after preparing the fourth liquid containing an emulsifier, flavor, and solvent, 0.40 parts by weight of the third liquid based on 100 parts by weight of the first liquid was added to the reactor mixed with the third liquid, and then heated at 2,000 rpm at 40°C. Stirring was performed at high speed for 30 minutes. At this time, the composition of the fourth liquid is shown in Table 6 below.
다음으로, 제4액이 혼합된 반응기의 온도를 25 ~ 28℃로 낮춘 후, pH 조절제인 알지닌을 제1액 100 중량부에 대하여 0.134 중량부의 양으로 투입한 후, 25 ~ 28℃ 하에서 2,500rpm 속도로 30분간 교반을 수행하였다.Next, after lowering the temperature of the reactor in which the fourth liquid was mixed to 25 to 28°C, arginine, a pH adjuster, was added in an amount of 0.134 parts by weight based on 100 parts by weight of the first liquid, and then reacted at 2,500°C at 25 to 28°C. Stirring was performed at rpm speed for 30 minutes.
다음으로, 진주 추출물 및 천연식물 복합 추출물을 포함하는 기능성 추출물, 락토바실러스발효 용해물, 콜라겐 합성 촉진제 및 향료를 포함하는 제5액을 제조한 후, 알지닌이 혼합된 반응기에 제1액 100 중량부에 대하여 제5액 14.49 중량부로 pH조절제가 혼합된 반응기에 투입한 후, 25 ~ 28℃ 하에서 2,000rpm 속도로 30분간 교반을 수행하였다. 이때, 제5액의 조성은 하기 표 7과 같다.Next, after preparing the fifth liquid containing a functional extract including pearl extract and natural plant complex extract, Lactobacillus fermentation lysate, collagen synthesis promoter, and fragrance, 100 weight of the first liquid was added to the reactor mixed with arginine. 14.49 parts by weight of the fifth liquid was added to the reactor mixed with the pH adjuster, and then stirred at 2,000 rpm for 30 minutes at 25 to 28°C. At this time, the composition of the fifth liquid is shown in Table 7 below.
이때, 진주 추출물은 진주 100g을 분쇄한 후 3L의 70 부피% 에탄올 수용액을 용매로 사용하여 12시간 가온 환류추출한 후, 냉침시키고, 1.2㎛ 투과 사이즈를 갖는 여과지로 여과하여 여과액을 수득한 다음, 수득된 여과액을 감압농축 및 감압 건조로 농축한 후, 건조 및 분쇄하여 제조한 것을 사용하였다.At this time, the pearl extract was obtained by grinding 100 g of pearls, extracting under reflux for 12 hours using 3L of 70% by volume ethanol aqueous solution as a solvent, followed by cold soaking, and filtering through filter paper with a penetration size of 1.2㎛ to obtain a filtrate. The obtained filtrate was concentrated under reduced pressure and dried under reduced pressure, then dried and pulverized.
그리고, 핑거루트뿌리줄기 추출물은 에탄올 추출물의 물 분획물로서, 다음과 같은 공정으로 제조한 핑거루트뿌리줄기 에탄올 추출물의 물 분획물을 사용하였다.In addition, the finger root rhizome extract is the water fraction of the ethanol extract, and the water fraction of the finger root rhizome ethanol extract prepared through the following process was used.
핑거루트뿌리줄기 분말 100g을 취하여 에탄올 1L를 넣고 셰이커를 이용하여 24시간 동안 25℃에서 추출하였다. 다음으로, 필터(Whatman No.2 filter paper)를 이용하여 필터링하여 핑거루트뿌리줄기 에탄올 추출물을 수득하였다. 핑거루트뿌리줄기 에탄올 추출물 1L 중 100ml를 취하여 증류수를 200ml 첨가하였다. 다음으로, 핑거루트뿌리줄기 에탄올 추출물과 증류수의 혼합물을 진공 상태에서 농축하여 에탄올을 모두 날린 후 분액 깔대기에 옮겼다. 여기에 디클로로포름 총 2L를 넣고 충분히 셰이킹(shaking)하여 방치한 뒤 분리시켰고 하층액을 수집하여 농축하였다. 다음으로, 디클로로포름 분획 후에는 에틸아세테이트 총 1L를 넣고 충분히 셰이킹하여 방치한 뒤 상층액을 분리한 다음 하층액을 동결건조하여 물 분획물을 수득한 후, 이를 동결 건조하여 핑거루트뿌리줄기 에탄올 추출물의 물 분획물 건조 분말을 수득하였다.Take 100g of finger root rhizome powder, add 1L of ethanol, and extract at 25°C for 24 hours using a shaker. Next, an ethanol extract of finger root rhizome was obtained by filtering using a filter (Whatman No.2 filter paper). 100ml of 1L of finger root rhizome ethanol extract was taken and 200ml of distilled water was added. Next, the mixture of finger root rhizome ethanol extract and distilled water was concentrated in a vacuum, all ethanol was removed, and then transferred to a separatory funnel. A total of 2L of dichloroform was added here, shaken sufficiently, left to stand, and then separated, and the lower layer was collected and concentrated. Next, after the dichloroform fractionation, a total of 1L of ethyl acetate was added, shaken sufficiently, left to stand, the supernatant was separated, and the lower layer was freeze-dried to obtain a water fraction, which was then freeze-dried to obtain an ethanol extract of finger root rhizome. A dry powder of the water fraction was obtained.
그리고, 천연식물 복합 추출물의 조성비는 하기 표 8과 같으며, 핑거루트뿌리줄기 추출물 외에 다른 식물 추출물은 상업적으로 구매하였다.In addition, the composition ratio of the natural plant complex extract is shown in Table 8 below, and other plant extracts other than the finger root rhizome extract were purchased commercially.
다음으로, 제5액을 혼합 교반하여 제조한 용액을 여과 및 탈포한 후, 숙성시켜서 최종적으로 화장료를 제조하였다. 제조된 화장료는 앰플 제형이었으며, 25℃에서 점도 14,000 ~ 16,000cP 및 pH 6.4 ~ 6.6 정도였다.Next, the solution prepared by mixing and stirring the fifth liquid was filtered and degassed, and then aged to finally prepare a cosmetic. The manufactured cosmetic was in an ampoule formulation, and had a viscosity of 14,000 to 16,000 cP and a pH of about 6.4 to 6.6 at 25°C.
비교예 1 : 피부탄력 화장료의 제조Comparative Example 1: Preparation of skin elasticity cosmetic
한국 등록특허 10-2288066호에 개시된 제1혼합제(유언제, 유화제, 착향제), 제2혼합제(정제수, 아데노신, 나이아신아마이드) 및 제3혼합제(천연식물유래 추출물, 천연식물유래 발효여과물, 컨디셔닝제, 안정제, 보전제, 금속이온봉쇄제)를 각각 제조한 후, 다음과 같은 공정을 통해, 피부탄력 화장료를 제조하였다.Disclosed in Korean Patent No. 10-2288066 are the first mixture (sulfur agent, emulsifier, flavoring agent), the second mixture (purified water, adenosine, niacinamide), and the third mixture (natural plant-derived extract, natural plant-derived fermentation filtrate, After preparing the conditioning agent, stabilizer, preservative, and metal ion sequestrant), skin elasticity cosmetics were prepared through the following process.
하기 표 9에서 제3혼합제의 컨디셔닝제는 아세틸헥사펩타이드-8(Acetyl Hexapeptide-8), 카퍼트라이펩타이드-1(Copper Tripeptide-1), 에스에이치올리고펩타이드-10(sh-Oligopeptide-10), 부틸렌글라이콜(Butylene Glycol), 프로필렌글라이콜(Propylene Glycol), 하이알루로닉애씨드(Hyaluronic Acid), 메틸퍼플루오로이소부틸에터(Methyl Perfluoroisobutyl Ether)를 동일 중량비로 혼합하여 제조한 것을 사용하였다.In Table 9 below, the conditioning agents of the third mixture are Acetyl Hexapeptide-8, Copper Tripeptide-1, sh-Oligopeptide-10, and Butylene Glyph. It was prepared by mixing Butylene Glycol, Propylene Glycol, Hyaluronic Acid, and Methyl Perfluoroisobutyl Ether in equal weight ratios. .
제1혼합제를 제1용기에 투입에 투입, 분산, 용해 및 혼합한 후(11단계), 제2혼합제를 분산, 용해 및 혼합하였다(21단계), 다음으로, 제3혼합제를 분산, 용해 및 혼합하였다(31단계). 상기 11단계에서 혼합된 제1혼합제와, 제21단계에서 혼합된 제2혼합제 및 제31단계에서 혼합된 제3혼합제는 각각 유화기로 이송되어 32단계에서 유화기 등에서 혼합 교반되었다. 그리고, 상기 32단계에서 혼합교반된 혼합물은 여과(제33단계) 후, 진공탈포(34단계)를 거쳐 저장탱크로 이송되어 저장 및 숙성(35단계)과정을 수행하여 피부탄력 화장료를 제조하였다. 제조한 화장료는 용기에 투입하여 보관하였다.After the first mixture was added to the first container, dispersed, dissolved, and mixed (step 11), the second mixture was dispersed, dissolved, and mixed (step 21). Next, the third mixture was dispersed, dissolved, and mixed. Mixed (step 31). The first mixture mixed in step 11, the second mixture mixed in step 21, and the third mixture mixed in step 31 were each transferred to an emulsifier and mixed and stirred in an emulsifier, etc. in step 32. Then, the mixture mixed and stirred in step 32 was filtered (step 33), vacuum degassed (step 34), transferred to a storage tank, and subjected to storage and aging (step 35) to prepare a skin elasticity cosmetic. The manufactured cosmetics were placed in a container and stored.
(10)First mixture
(10)
(20)Second mixture
(20)
(30)Third mixture
(30)
실험예 7 : 눈가 주름 개선 효과 측정Experimental Example 7: Measurement of wrinkle improvement effect around the eyes
실시예 1 및 비교예 1의 화장료의 사용 전후 눈가 주름 개선 효과를 측정하였으며, PRIMOS(Phaseshift rapid in-vivo measurement of skin)를 이용한 눈가 주름 측정을 수행하였고, 평가 결과를 하기 표 10에 나타내었다. PRIMOS 분석 변수로는 Ra와 R3z를 선정하였으며, 변수 Ra(Arithmetic roughness average)는 PRIMOS로 측정된 주름의 거칠기 단면 피크(peak)에 대한 산술 평균값으로 Ra값이 작아질수록 피부 주름의 깊이가 낮아져 주름이 개선됨을 의미하며, 단위는 ㎛이다.The effect of improving wrinkles around the eyes was measured before and after using the cosmetics of Example 1 and Comparative Example 1. Wrinkles around the eyes were measured using PRIMOS (Phaseshift rapid in-vivo measurement of skin), and the evaluation results are shown in Table 10 below. Ra and R3z were selected as PRIMOS analysis variables, and the variable Ra (Arithmetic roughness average) is the arithmetic mean value of the peak of the roughness cross-section of wrinkles measured with PRIMOS. As the Ra value decreases, the depth of skin wrinkles decreases, resulting in wrinkles. This means improvement, and the unit is ㎛.
변수 R3z(Base roughness depth)는 R3z1부터 R3z5까지 5가지의 단일 거칠기 깊이에 대한 산술 평균으로 나타낸다. 단일 거칠기 깊이는 거칠기 단면의 단일 평가 거리(Ir)에서 세번째로 높은 단면 peak과 세번째로 깊은 곡선 사이의 수직거리를 의미한다. R3z의 값이 작아질수록 피부의 주름 깊이가 낮아짐을 의미하며 주름 개선이 되었음을 의미한다. 단위는 ㎛이다. 일시적 눈가 주름 개선율은 하기 수학식 1에 따라 계산하였다.The variable R3z (Base roughness depth) is expressed as the arithmetic mean of five single roughness depths from R3z1 to R3z5. Single roughness depth refers to the vertical distance between the third highest cross section peak and the third deepest curve in the single evaluation distance (Ir) of the roughness cross section. The smaller the value of R3z, the lower the depth of wrinkles in the skin and the improvement in wrinkles. The unit is ㎛. The temporary improvement rate of wrinkles around the eyes was calculated according to
[수학식 1][Equation 1]
눈가주름 개선율(%) = 100% - {(A-B)/B}*100%Improvement rate of eye wrinkles (%) = 100% - {(A-B)/B}*100%
수학식 1에서, A는 제품 사용 후 측정값이고, B는 제품 사용 전 측정값이다.In
눈가 주름을 분석한 결과, 비교예 1 및 실시예 1의 화장료 모두 사용 전과 비교하여 사용 후에서 변수 Ra와 R3z 모두 통계적으로 유의차 있게 일시적 눈가 주름 개선 효과를 나타냈으며(p<0.05), 비교예 1 보다 실시예 1이 상대적으로 좀 더 우수한 눈가 주름 개선율을 보였다.As a result of analyzing wrinkles around the eyes, both the cosmetics of Comparative Example 1 and Example 1 showed a statistically significant temporary improvement in wrinkles around the eyes after use compared to before use for both variables Ra and R3z (p<0.05), Comparative Example Example 1 showed a relatively better improvement rate of wrinkles around the eyes than Example 1.
실험예 8 : 피부 탄력 개선 효과 측정Experimental Example 8: Measurement of skin elasticity improvement effect
실시예 1 및 비교예 1의 화장료의 사용 전후 피부 탄력 개선 효과를 측정하였으며, Cutometer(Courage and Khazaka Electronic, Germany)를 이용하여 시험 부위를3회 측정하였으며, 3개의 값을 이용해 평균값을 구하였다. 측정 부위는 눈꼬리에서 3cm 떨어진 지점으로 측정하였다. Cutometer는 피부 표면에 음압을 가하여 피부가 탐침기 안으로 흡입되는 정도를 피부를 통과할 수 있는 광학시스템을 이용하여 측정한다. 이때 사용되는 빛은 적외선으로 피부를 통과하면서 감소되는 빛의 세기와 피부를 통과하지 않는 빛의 세기의 비율로 탄력의 정도를 측정한다. 탄력에 대한 Cutometer 측정 변수로는 R2(A.U.)를 선정하였다.The effect of improving skin elasticity before and after using the cosmetics of Example 1 and Comparative Example 1 was measured. The test area was measured three times using a Cutometer (Courage and Khazaka Electronic, Germany), and the average value was calculated using the three values. The measurement area was measured 3cm away from the corner of the eye. Cutometer applies negative pressure to the skin surface and measures the degree to which the skin is sucked into the probe using an optical system that can pass through the skin. The light used at this time is infrared, and the degree of elasticity is measured by the ratio of the intensity of light that decreases as it passes through the skin and the intensity of light that does not pass through the skin. R2 (A.U.) was selected as the Cutometer measurement variable for elasticity.
변수 R2은 피부가 늘어날 수 있는 최대치에서 피부가 총 수축되는 길이와의 비를 나타내며, 피부의 재변형력인 총체적인 탄성을 나타낸다. 이 변수의 값은 1에 가까울수록 더욱 탄성적임을 의미한다. 피부 탄력 개선율은 하기 수학식 1에 따라 계산하였다. 측정은 사용 전(0주), 사용 2주 후 및 사용 4주 후 측정하였다.The variable R2 represents the ratio of the total contracted length of the skin to the maximum that the skin can stretch, and represents the overall elasticity, which is the re-deformability of the skin. The closer the value of this variable is to 1, the more elastic it is. The skin elasticity improvement rate was calculated according to
평가 기간 동안 시험 제품에 의한 피부 유해사례는 발생하지 않았으며, 피부 탄력 측정 결과는 하기 표 11과 같다.No skin adverse events occurred due to the test product during the evaluation period, and the skin elasticity measurement results are shown in Table 11 below.
[수학식 2][Equation 2]
피부 탄력 개선율(%) = {(B-A)/B}*100%Skin elasticity improvement rate (%) = {(B-A)/B}*100%
수학식 2에서, A는 제품 사용 후 R2 측정값이고, B는 제품 사용 전 R2 측정값이다.In
R2 측정값0 weeks
R2 측정값2 weeks later
R2 measure
R2 측정값4 weeks later
R2 measure
피부탄력 개선율(%)4 weeks later
Skin elasticity improvement rate (%)
눈가 주름을 분석한 결과, 비교예 1 및 실시예 1의 화장료 모두 사용 전과 비교하여 사용 후에서 피부 탄력 개선 효과를 나타냈으며(p<0.05), 비교예 1 보다 실시예 1이 상대적으로 좀 더 우수한 눈가 주름 개선율을 보였다.As a result of analyzing the wrinkles around the eyes, both the cosmetics of Comparative Example 1 and Example 1 showed an effect of improving skin elasticity after use compared to before use (p<0.05), and Example 1 was relatively better than Comparative Example 1. There was an improvement in wrinkles around the eyes.
실험예 9 : 티로시나제 효소 활성 저해능 평가Experimental Example 9: Evaluation of tyrosinase enzyme activity inhibition ability
실시예 1의 화장료에 대한 미백 활성 효과는 티로시나제 효소 활성 저해능을 통해 평가하였다. 0.1M sodium phosphate buffer(pH 6.9) 1mL, 다양한 농도의 실시예 1의 화장료 시료, mushroom tyrosinase(1 KU/mL) 30㎕를 혼합하고 37℃에서 10분간 반응시킨 후 기질로서 1.5mM L-tyrosine 30㎕를 혼합하여 25℃에서 2분간 반응시켜 반응액 중에 생성된 DOPA chrome을 475nm에서 측정하였고 그 결과를 표 12에 나타내었다. 대조군의 흡광도를 Abcontrol 이라 하고 시료의 흡광도를 Absample 로 하여 하기 수학식 3에 따라 계산하였다.The whitening activity effect of the cosmetic of Example 1 was evaluated through its ability to inhibit tyrosinase enzyme activity.
[수학식 3][Equation 3]
티로시나제 효소 활성 저해율(%) = (1-Absample)/Abcontrol*100%Tyrosinase enzyme activity inhibition rate (%) = (1-Ab sample )/Ab control *100%
상기 표 12의 티로시나제 효소 활성 저해율 평가를 통해, 본 발명의 화장료가 티로시나제 효소의 활성 저해를 통한 피부 미백 효과가 있음을 확인할 수 있었다.Through the evaluation of the tyrosinase enzyme activity inhibition rate in Table 12 above, it was confirmed that the cosmetic of the present invention has a skin whitening effect through inhibiting the activity of the tyrosinase enzyme.
상기 실시예 및 실험예를 통하여, 본 발명의 화장료가 피부 미백 및 피부 주름 개선 등 다양한 효과가 있는 것을 확인할 수 있었으며, 이러한 본 발명의 화장료는 다양한 피부용 화장품의 화장료를 제공할 수 있음을 확인할 수 있었다.Through the above examples and experimental examples, it was confirmed that the cosmetic of the present invention has various effects such as skin whitening and improvement of skin wrinkles, and it was confirmed that the cosmetic of the present invention can provide a variety of cosmetics for skin. .
본 발명의 단순한 변형이나 변경은 이 분야의 통상의 지식을 가진 자에 의해서 용이하게 실시될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.Simple modifications or changes to the present invention can be easily implemented by those skilled in the art, and all such modifications or changes can be considered to be included in the scope of the present invention.
Claims (10)
제1액이 제조된 반응기에 제2액을 투입한 후, 2000 ~ 3000rpm 하에서 20 ~ 40분 동안 교반을 수행하는 2단계;
2단계를 수행한 반응기에 제3액을 투입한 후, 1500 ~ 2500rpm 하에서 20 ~ 40분 동안 교반을 수행하는 3단계;
3단계를 수행한 반응기에 제4액을 투입한 후, 1500 ~ 2500rpm 하에서 20 ~ 40분 동안 교반을 수행하는 4단계;
4단계를 수행한 반응기에 pH 조절제를 투입한 후, 2000 ~ 3000rpm 하에서 20 ~ 40분 동안 교반을 수행하는 5단계;
5단계를 수행한 반응기에 제5액을 투입한 후, 1500 ~ 2500rpm 하에서 20 ~ 40분 동안 교반을 수행하는 6단계;
6단계를 수행한 혼합액을 여과 및 탈포하는 7단계; 및
7단계를 수행한 혼합액을 숙성시키는 8단계;를 포함하는 공정을 수행하며,
상기 제1액은 점도조절제 및 정제수를 포함하고,
상기 제2액은 잔탄검; 및 글리세린 및 부틸렌글라이콜을 포함하는 보습제;를 포함하며,
상기 제3액은 메틸글루세스-20, 나이아신아마이드, 글리세레스-26, 소듐하이알루로네이트, 알란토인, 하이드롤라이즈드 콜라겐 및 아데노신 중에서 선택된 1종 이상을 포함하는 피부컨디셔닝제; 습윤제; 및 용매;를 포함하고,
상기 제4액은 유화제, 향료 및 용매를 포함하며,
상기 pH 조절제는 알지닌을 포함하며,
상기 제5액은 진주 추출물 및 천연식물 복합 추출물을 포함하는 기능성 추출물; 락토바실러스발효 용해물; 및 콜라겐 합성 촉진제;를 포함하고,
상기 천연식물 복합 추출물은 핑거루트뿌리줄기 추출물, 병풀 추출물, 비타민나무 추출물, 포트마리골드추출물, 녹차 추출물, 마트리카리아 추출물, 뽕나무잎 추출물, 산사나무열매 추출물, 페퍼민트 추출물, 히비스커스꽃 추출물 및 로즈마리 추출물을 포함하며,
상기 콜라겐 합성 촉진제는 알에이치-올리고펩타이드-1를 포함하는 것을 특징으로 하는 자연유래 식물 핑거루트의 피부탄력 성분 소재를 활용한 앰플 제형의 피부탄력 개선 화장료의 제조방법.Step 1 of preparing a first liquid by adding purified water and a viscosity modifier to the reactor and stirring for 30 to 50 minutes at 3000 to 4000 rpm;
Step 2 of adding the second liquid to the reactor where the first liquid was prepared and then stirring for 20 to 40 minutes at 2000 to 3000 rpm;
Step 3 of adding the third liquid to the reactor that performed step 2 and then stirring for 20 to 40 minutes at 1500 to 2500 rpm;
Step 4 of adding the fourth liquid to the reactor that performed step 3 and then stirring for 20 to 40 minutes at 1500 to 2500 rpm;
Step 5 of adding a pH adjuster to the reactor that performed step 4 and then stirring for 20 to 40 minutes at 2000 to 3000 rpm;
Step 6 of adding the fifth liquid to the reactor that performed step 5 and then stirring for 20 to 40 minutes at 1500 to 2500 rpm;
Step 7 of filtering and defoaming the mixed solution from step 6; and
Performing a process including step 8 of maturing the mixed solution after performing step 7,
The first liquid contains a viscosity modifier and purified water,
The second liquid includes xanthan gum; and a moisturizing agent containing glycerin and butylene glycol.
The third liquid is a skin conditioning agent containing one or more selected from methylgluceth-20, niacinamide, glycerol-26, sodium hyaluronate, allantoin, hydrolyzed collagen, and adenosine; humectant; and solvent;
The fourth liquid contains an emulsifier, fragrance, and solvent,
The pH adjuster includes arginine,
The fifth liquid is a functional extract including pearl extract and natural plant complex extract; Lactobacillus fermentation lysate; And a collagen synthesis promoter;
The natural plant complex extract includes finger root rhizome extract, centella asiatica extract, vitamin tree extract, port marigold extract, green tea extract, Matricaria extract, mulberry leaf extract, hawthorn fruit extract, peppermint extract, hibiscus flower extract and rosemary extract. Includes,
The collagen synthesis accelerator is a method of producing an ampoule-type skin elasticity improving cosmetic using the skin elasticity ingredient material of finger root, a naturally derived plant, characterized in that it contains RH-oligopeptide-1.
3단계는 제1액 100 중량부에 대하여, 제3액을 12 ~ 16 중량부로 투입하고,
4단계는 제1액 100 중량부에 대하여, 제4액을 0.2 ~ 1.0 중량부로 투입하며,
6단계는 제1액 100 중량부에 대하여, 제5액을 13 ~ 16 중량부로 투입하는 것을 특징으로 하는 자연유래 식물 핑거루트의 피부탄력 성분 소재를 활용한 앰플 제형의 피부탄력 개선 화장료의 제조방법.According to claim 1, in the second step, 7 to 12 parts by weight of the second liquid is added to 100 parts by weight of the first liquid,
In the third step, 12 to 16 parts by weight of the third liquid is added to 100 parts by weight of the first liquid,
In step 4, 0.2 to 1.0 parts by weight of the fourth liquid is added to 100 parts by weight of the first liquid,
Step 6 is a method of manufacturing an ampoule-type skin elasticity improvement cosmetic using the skin elasticity component of finger root, a naturally derived plant, characterized in that 13 to 16 parts by weight of the fifth solution is added to 100 parts by weight of the first solution. .
상기 제1액은 점도조절제 및 정제수를 포함하고,
상기 제2액은 잔탄검; 및 글리세린 및 부틸렌글라이콜을 포함하는 보습제;를 포함하며,
상기 제3액은 메틸글루세스-20, 나이아신아마이드, 글리세레스-26, 소듐하이알루로네이트, 알란토인, 하이드롤라이즈드 콜라겐(Hydrolyzed Collagen) 및 아데노신 중에서 선택된 1종 이상을 포함하는 피부컨디셔닝제; 습윤제; 및 용매;를 포함하고,
상기 제4액은 유화제, 향료 및 용매를 포함하며,
상기 제5액은 진주 추출물 및 천연식물 복합 추출물을 포함하는 기능성 추출물; 락토바실러스발효 용해물; 및 콜라겐 합성 촉진제;를 포함하고,
상기 천연식물 복합 추출물은 핑거루트뿌리줄기 추출물, 병풀 추출물, 비타민나무 추출물, 포트마리골드추출물, 녹차 추출물, 마트리카리아 추출물, 뽕나무잎 추출물, 산사나무열매 추출물, 페퍼민트 추출물, 히비스커스꽃 추출물 및 로즈마리 추출물을 포함하며,
상기 콜라겐 합성 촉진제는 알에이치-올리고펩타이드-1를 포함하는 것을 특징으로 하는 자연유래 식물 핑거루트의 피부탄력 성분 소재를 활용한 앰플 제형의 피부탄력 개선 화장료.For 100 parts by weight of the first liquid, 7 to 12 parts by weight of the second liquid, 12 to 16 parts by weight of the third liquid, 0.2 to 1.0 parts by weight of the fourth liquid, and 13 to 16 parts by weight of the fifth liquid,
The first liquid contains a viscosity modifier and purified water,
The second liquid includes xanthan gum; and a moisturizing agent containing glycerin and butylene glycol.
The third liquid is a skin conditioning agent containing one or more selected from Methyl Gluceth-20, Niacinamide, Glycereth-26, Sodium Hyaluronate, Allantoin, Hydrolyzed Collagen, and Adenosine; humectant; and solvent;
The fourth liquid contains an emulsifier, fragrance, and solvent,
The fifth liquid is a functional extract including pearl extract and natural plant complex extract; Lactobacillus fermentation lysate; And a collagen synthesis promoter;
The natural plant complex extract includes finger root rhizome extract, centella asiatica extract, vitamin tree extract, port marigold extract, green tea extract, Matricaria extract, mulberry leaf extract, hawthorn fruit extract, peppermint extract, hibiscus flower extract and rosemary extract. Includes,
The collagen synthesis accelerator is an ampoule-type skin elasticity improvement cosmetic using skin elasticity ingredient material of finger root, a naturally derived plant, characterized in that it contains RH-oligopeptide-1.
상기 제2액은 잔탄검 0.5 ~ 1.5 중량% 및 나머지 잔량의 보습제를 포함하며,
상기 제3액은 피부컨디셔닝제 77 ~ 85 중량%, 습윤제 1.0 ~ 3.0 중량% 및 나머지 잔량의 용매를 포함하는 것을 특징으로 하는 자연유래 식물 핑거루트의 피부탄력 성분 소재를 활용한 앰플 제형의 피부탄력 개선 화장료.The method of claim 3, wherein the first liquid contains 0.10 to 0.25% by weight of a viscosity modifier and a remaining amount of purified water,
The second liquid contains 0.5 to 1.5% by weight of xanthan gum and the remaining amount of moisturizer,
The third liquid contains 77 to 85% by weight of a skin conditioning agent, 1.0 to 3.0% by weight of a humectant, and the remaining amount of solvent. Skin elasticity of an ampoule formulation using the skin elasticity ingredient material of finger root, a naturally derived plant. Improved cosmetics.
제5액은 락토바실러스발효 용해물 3.5 ~ 8.0 중량%, 콜라겐 합성 촉진제 1.0 ~ 2.5 중량%, 및 나머지 잔량의 기능성 추출물을 포함하고,
상기 기능성 추출물은 진주 추출물 및 천연식물 복합 추출물을 1 : 3.5 ~ 5.0 중량비로 포함하는 것을 특징으로 하는 자연유래 식물 핑거루트의 피부탄력 성분 소재를 활용한 앰플 제형의 피부탄력 개선 화장료.The method of claim 3, wherein the fourth liquid contains 20 to 28% by weight of emulsifier, 5 to 20% by weight of fragrance, and the remaining amount of solvent,
The fifth liquid contains 3.5 to 8.0% by weight of Lactobacillus fermentation lysate, 1.0 to 2.5% by weight of collagen synthesis promoter, and the remaining amount of functional extract,
The functional extract is an ampoule-type skin elasticity improvement cosmetic using the skin elasticity ingredient of finger root, a naturally derived plant, characterized in that it contains pearl extract and natural plant complex extract at a weight ratio of 1:3.5 to 5.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210183402A KR102609952B1 (en) | 2021-12-21 | 2021-12-21 | Ample type cosmetic composition improving skin elasticity, Manufacturing method of the same and Ample type comsmetics improving skin elasticity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210183402A KR102609952B1 (en) | 2021-12-21 | 2021-12-21 | Ample type cosmetic composition improving skin elasticity, Manufacturing method of the same and Ample type comsmetics improving skin elasticity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230095136A KR20230095136A (en) | 2023-06-29 |
KR102609952B1 true KR102609952B1 (en) | 2023-12-05 |
Family
ID=86946392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210183402A KR102609952B1 (en) | 2021-12-21 | 2021-12-21 | Ample type cosmetic composition improving skin elasticity, Manufacturing method of the same and Ample type comsmetics improving skin elasticity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102609952B1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102288066B1 (en) | 2019-08-19 | 2021-08-11 | 이호규 | Method for extracting Boesenbergia pandurate extracts and cosmetic compositions containing the Boesenbergia pandurate extracts for skin elasticity and manufacturing method thereof |
-
2021
- 2021-12-21 KR KR1020210183402A patent/KR102609952B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20230095136A (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101936294B1 (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
KR20090055309A (en) | A cosmetic composition for skin whitening and treating wrinkles | |
KR101988489B1 (en) | Functional cosmetic composition for anti-dust and anti-inflamatory containing natural extract as an effective ingredient and functional cosmetic including the same | |
KR20100043655A (en) | A cosmetic composition for stabilizing vitamin c | |
KR101292837B1 (en) | Composition for skin wrinkle improvement comprising extracts of Junglans mandshurica MAXIM as an active ingredient | |
KR100785505B1 (en) | Oriental medicine material extract having antioxidation effect and whitening effect, manufacturing method of those extract and cosmetics comprising the oriental medicine material | |
KR101182032B1 (en) | Composition comprising the essential oil extract of Laminaria japonica showing anti-oxidant activity | |
KR102239784B1 (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
KR20160002125A (en) | Cosmetic composition containing natural herb extracts | |
KR20150125662A (en) | Bioactive compositions from theacea plants and use thereof in beverages, functional foods, nutriceuticals, supplements and the like | |
WO2009135352A1 (en) | A plum tree extract, a method for preparing the plum tree extract and use thereof | |
KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
KR101954275B1 (en) | Cosmetic compositions containing complex extract of gold kiwi peel and dragon fruit peel, and method manufacturing the same | |
KR102609952B1 (en) | Ample type cosmetic composition improving skin elasticity, Manufacturing method of the same and Ample type comsmetics improving skin elasticity | |
KR102069641B1 (en) | Functional cosmetic composition for anti-dust and anti-inflamatory containing seafood extract and functional cosmetic including the same | |
KR102609955B1 (en) | Emulsion type cosmetic composition improving skin elasticity, Manufacturing method of the same and Emulsion type comsmetics improving skin elasticity | |
KR20200134929A (en) | Cosmetic composition containing complex medicinal herbs extract for skin whitening and anti-wrinkle effect and manufacturing method thereof | |
KR101293418B1 (en) | Fermented extract of Oriental medicine plant complex, method for manufacturing the same and cosmetic compositions comprising the oriental medicine plant complex | |
KR100515419B1 (en) | Whitening cosmetics composition comprising natural herb extracts | |
KR101611881B1 (en) | Method for producing Phellinus linteus mycelium pressurized extract with increased antioxidant and whitening activity cultured in Mori ramulus medium | |
KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
KR20100092922A (en) | A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome | |
KR101851153B1 (en) | Manufacturing method of fermented rhemannia glutinosa and fermented rhemannia glutinosa manufactured by same method | |
CN113631227A (en) | Antiaging agent, antioxidant, antiinflammatory agent, whitening agent, and cosmetic | |
KR100689237B1 (en) | A pharmaceutical and food composition comprising an extract of Lespedeza bicolor having anti-oxidative activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |